TW295587B - - Google Patents

Download PDF

Info

Publication number
TW295587B
TW295587B TW83100925A TW83100925A TW295587B TW 295587 B TW295587 B TW 295587B TW 83100925 A TW83100925 A TW 83100925A TW 83100925 A TW83100925 A TW 83100925A TW 295587 B TW295587 B TW 295587B
Authority
TW
Taiwan
Prior art keywords
formula
compound
ministry
page
amino
Prior art date
Application number
TW83100925A
Other languages
Chinese (zh)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19934316019 external-priority patent/DE4316019A1/en
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of TW295587B publication Critical patent/TW295587B/zh

Links

Landscapes

  • Paper (AREA)

Description

895&Β7 A6 B6 五、發明説明( 骨骼系統病變之療法已日漸重要。例如:骨疏鬆症即 為一種常見之骨胳病變。許多種骨疏鬆症大量流失骨路組 織,因此最後喪失了骨骼之機轉安定性。健康人之骨母細 胞與触骨細胞之形成速率可使骨赂形成與骨路再吸收達成 平衡。骨疏鬆症之這種平衡則受到干擾,因此出現骨路破 壞現象。 已知胍烷基-1,1-雙膦酸衍生物適用於預防及/或治療 骨疏鬆症(EP 0 546 548)。 在致力於探求其他治療及預防骨疏鬆症,且副作用較 少之活性化合物時,已發現根據本發明之胍烷基_1,1-雙膦 酸可降低骨再吸收作用。 因此本發明係有關式I a、I b或I c之互變異構型化 合物 0 11/895 & B7 A6 B6 V. Description of the invention (The treatment of skeletal system diseases has become increasingly important. For example: osteoporosis is a common skeletal disease. Many types of osteoporosis lose a lot of bone tissue, so they finally lose their bones The mechanism is stable. The rate of formation of osteoblasts and contact bone cells in healthy people can balance bone formation and bone resorption. The balance of osteoporosis is disturbed, so bone destruction occurs. Known guanidinyl-1,1-bisphosphonic acid derivatives are suitable for the prevention and / or treatment of osteoporosis (EP 0 546 548). In an effort to explore other treatment and prevention of osteoporosis, with active compounds with fewer side effects At this time, it has been found that the guanidinyl-1,1-bisphosphonic acid according to the present invention can reduce bone resorption. Therefore, the present invention relates to tautomeric compounds of formula I a, I b or I c

OROR

NH IIC-N-C-N-CH II I INH IIC-N-C-N-CH II I I

/CH \ .OR/ CH \ .OR

OR (I。 ............................................................................裝......................訂........線 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 -3 - 本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐) 五、發明説明(OR (I. .............................................. ........................ Pretend ........................ ... order ........ line (please read the precautions on the back before filling out this page) Printed by the Staff Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs-3-This paper standard applies to China National Standard (CNS) A 4 Specifications (210X297mm) 5. Description of invention (

NH R—C-N-C-N-CH II IΟ Η on ρ ρ π ο/CH\ A6 B6 R R R R ο ο ο ο b (請先閲讀背面之注意事項再填寫本頁)NH R—C-N-C-N-CH II IΟ Η on ρ ρ π ο / CH \ A6 B6 R R R R ο ο ο ο b (please read the precautions on the back before filling this page)

R NIH I cno H c 驗 2 N H 0 NI c R R R R o o o o// \ / on p p M o /H\ / c\ 與/或式I a、I b或I c化合物之生理上可接受之鹽; R如下列定義, I)如式V之自由基R NIH I cno H c test 2 NH 0 NI c RRRR oooo // \ / on pp M o / H \ / c \ and / or physiologically acceptable salts of compounds of formula I a, I b or I c; R As defined below, I) Free radicals of formula V

經濟部中央標準局貝工消费合作社印製 式中R11或R12如下列定義 a) Rn-S(0)n或Printed by the Beigong Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs, R11 or R12 is as defined below a) Rn-S (0) n or

本紙張尺度適用中國國家標準(CHS)甲4规格(210x297公釐) 五、發明説明( A6 B6 經濟部中央標準局員工消費合作社印製 式中R13為 1) (CfC,)-烷基, 2) (C5-C7)-環烷基, 3) 環戊基甲基, 4) 環己基甲基, 5) 苯基, 6) 經下列基團取代一至三次之苯基 6.1氟原子’ 6.2氯原子, 6.3甲基或 6.4甲氧基, 其中η為整數0,1或2 ’ 其中R14與R15相同或相異,且分別如下列定義·· υ氫原子, 2) (CrC,)-烷基., 3) 苯基, 4) 經下列基團取代一或二次之苯基: 4.1氟原子, . 4.2氯原子, 4.3甲基或 4.4甲氧基, 5) -(CH2)m-苯基,其中m為1至4之整數,或 6) -(CH2)m-苯基,其中m為1至4之整數,且苯基自 —5 — .................. ......... ................._ ......................裝......................訂............................線 {請先閲讀背面之注意事項再填寫本頁) 本紙張尺度逋用中國國家標準(CNS)甲4規格(210x297公釐) A6 B6 經濟部中央標準局員工消費合作社印製 五、發明説明( ) 由基經4.1至4.4所示之自由基一次或二次取代, 7) R14與R15共同形成4至7個碳原子之直鏈或分支鏈 ,鏈中可穿插下列基團: 7.1 Ο, 7.2 S或 7.3 NR10 其中 R1(>為1)氫原子或 2)曱基,或 8) R14與R15及所附接之氮原子共同形成: 8.1二氫吲哚, 8.2四氬奎琳,或 8.3四氫異喹啉環' 且其他取代基R11或R12分別代表 a) 氫原子, b) 鹵原子,如:氟、氣、溴或破原子, c) (CrC4)-烷基, d) 烷氧基, e) 苯氧基, f) 經下列基團取代一至三次之苯氧基 1) 氟或氯原子, 2) 甲基,或 3) 甲氧基, g) R13-S(0)n,其中η為整數η,1或2、且R13如上述定 一 6 — ..........:»..........;..............-......................................裝.........-............訂.....................線 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐) 2&S&S1 A6 B6 五、發明説明( 義,或This paper scale is applicable to the Chinese National Standard (CHS) A4 specification (210x297 mm). V. Description of the invention (A6 B6 R13 is 1 in the printed form of the Employees Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs) (CfC,)-alkyl, 2 ) (C5-C7) -Cycloalkyl, 3) Cyclopentylmethyl, 4) Cyclohexylmethyl, 5) Phenyl, 6) One to three times substituted phenyl with 6.1 fluorine atoms' 6.2 chlorine atoms , 6.3 methyl or 6.4 methoxy, where η is an integer 0, 1 or 2 'where R14 and R15 are the same or different, and are as defined below · · υ hydrogen atom, 2) (CrC,)-alkyl. , 3) Phenyl, 4) One or two times substituted phenyl by the following groups: 4.1 fluorine atom, .4.2 chlorine atom, 4.3 methyl or 4.4 methoxy, 5)-(CH2) m-phenyl, Where m is an integer from 1 to 4, or 6)-(CH2) m-phenyl, where m is an integer from 1 to 4, and phenyl is from -5 -... ..................................._ .................. .... installed ..................... ordered ........................... ...... Line {Please read the precautions on the back before filling out this page) This paper uses the Chinese National Standard (CNS) A4 specifications (210x297 Cli) A6 B6 Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy V. Invention description () Primary or secondary substitution by radicals as shown in 4.1 to 4.4, 7) R14 and R15 together form 4 to 7 carbon atoms Straight or branched chain, the following groups may be interspersed in the chain: 7.1 Ο, 7.2 S or 7.3 NR10 where R1 (> is 1) hydrogen atom or 2) methyl group, or 8) R14 and R15 and the attached Nitrogen atoms form together: 8.1 indoline, 8.2 tetrahydroquinoline, or 8.3 tetrahydroisoquinoline ring and other substituents R11 or R12 represent a) hydrogen atom, b) halogen atom, such as: fluorine, gas , Bromine or broken atom, c) (CrC4) -alkyl, d) alkoxy, e) phenoxy, f) phenoxy substituted one to three times with the following groups 1) fluorine or chlorine atom, 2) A Radical, or 3) methoxy, g) R13-S (0) n, where η is an integer η, 1 or 2, and R13 is as defined above 6 — .................. ». .........; ..............-......................... ............. installed ............-............ ordered .................. ........ Line (please read the precautions on the back before filling out this page) This paper scale is applicable to the Chinese National Standard (C NS) A 4 specifications (210X297 mm) 2 & S & S1 A6 B6 V. Description of invention (meaning, or

其中R14與R15如上述定義,或 Π)式VI自由基 R21Where R14 and R15 are as defined above, or Π) formula VI radical R21

經濟部中央標準局員工消費合作社印製 a) 氫原子, ' b) 鹵原子,如:氟,氯,溴、或破原子,或 c) (CrC12)-烷基, 其中R21,R22或R23中一個取代基亦可代表 1) n3 ’ 2) CN, 3) OH, 4) (CrC1())-烷氧基, 5) R24-CnH2n-〇m -其中m為數字0或1, η為數字0,1,2或3, R24為 一 7 — .........:'·: ............................. ......................I ......................ΤΤ.....................I (請先閲讀背面之注意事項再填窝本頁j 本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐) A6 A6Printed by the Staff Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs a) hydrogen atoms, b) halogen atoms, such as fluorine, chlorine, bromine, or broken atoms, or c) (CrC12) -alkyl groups, where R21, R22 or R23 One substituent may also represent 1) n3 '2) CN, 3) OH, 4) (CrC1 ())-alkoxy, 5) R24-CnH2n-〇m-where m is the number 0 or 1, η is the number 0, 1, 2 or 3, R24 is a 7 — .........: '·: .............................. ............................. I ...................... ΤΤ ..................... I (Please read the precautions on the back before filling in this page. J This paper size applies to China National Standard (CNS) A4 specifications (210X297mm) A6 A6

其中P為數字1,2或3,但是必須 n為數字0或1, 2) (cVc12卜環烷基, 3) 苯基, 4) P比>7定基, 5) 喳啉基或 6) 異喳啉基, 其中自由基3)至6)中之環系未經取代,或經下列 —個自由基取代: 3· 1氣原子, 3.2鼠原子, 3_3 CF,, j ~ 3_4甲基, 3·5甲氧基或 3.6 NR25R26, 其中R25與R26相同或相異,且分別如下列定義: 或 ::V.........................................................."......................裝.......................玎.....................線 (請先閱讀背面之注意事项再填寫本頁) 經濟部中央標準局貝工消费合作社印製 3.6.1氫原子,或 3.6.2 (CrC4)-烷基 瓜)式W自由基Where P is the number 1, 2 or 3, but n must be the number 0 or 1, 2) (cVc12 cycloalkyl, 3) phenyl, 4) P ratio > 7 definitive, 5) cinnoline or 6) Isodocinolyl, in which the ring systems in free radicals 3) to 6) are unsubstituted or substituted with one of the following free radicals: 3.1 gas atom, 3.2 rat atom, 3_3 CF, j ~ 3_4 methyl, 3.5 methoxy or 3.6 NR25R26, where R25 and R26 are the same or different, and are as defined below: or :: V ..................... ............................... " ........... ........... pretend ............................................................ ....... line (please read the precautions on the back before filling in this page) 3.6.1 hydrogen atom or 3.6.2 (CrC4) -alkyl melon printed by Beigong Consumer Cooperative of Central Bureau of Standards of the Ministry of Economic Affairs Free radical

(VII) 一 8 一 本紙張尺度適用t國國家標準(CHS)甲4規格(210X297公釐) 五、發明説明( 式中r3,’r32,r33或r34如下列定義. a)氫原子, 我· ⑴由原子如m或 c) -CN, 一、 d) -N〇2,e) -N,, f) -(CrC6)-燒基,直鏈或分支, Λ „35 _ 一乂 g) R -CnIl2n-Z- 其中n為數字〇 ’ 1 ’ 2,3,4 , 5.或6 ' -CnH2n-為直鏈或分支,且其中—個碳』虼基鏈 或氮原子置換,、 、j破氣,硫 R35為 1) 氨原子, 2) (C3-C6)-烯基, 3) (C5-C8)-環烷基, 4) (q-C8)-環烷基,係經一個羥基取代,或其中— 個亞甲基被氧,硫或氮原子置換,或 5) 苯基,未經取代或經選自下列丨至3個自由基取代 經濟部t央標準局貝工消费合作社印製 5.1鹵原子如··氟’氯,溴或破原子, 5.2 CF3, 5.3 CH「S(0)y, -9 本紙張尺度遑用中國國家標準(CNS)甲4规格(210X297公釐)(VII) One 8 one paper scale is applicable to the national standard (CHS) A 4 specifications (210X297 mm) of country t. 5. Description of the invention (where r3, r32, r33 or r34 are as defined below. A) Hydrogen atom, I · (1) by atoms such as m or c) -CN, one, d) -N〇2, e) -N ,, f)-(CrC6)-burned group, straight chain or branch, Λ „35 _ 一 乂 g) R -CnIl2n-Z- where n is a number 〇 '1' 2, 3, 4, 5. or 6 '-CnH2n- is a straight chain or branch, and wherein one of the carbon 晼 base chain or nitrogen atom replacement,,, j gas breaking, sulfur R35 is 1) ammonia atom, 2) (C3-C6) -alkenyl, 3) (C5-C8) -cycloalkyl, 4) (q-C8) -cycloalkyl, through a Hydroxyl substitution, or one of the methylene groups is replaced by oxygen, sulfur or nitrogen atoms, or 5) phenyl group, unsubstituted or substituted by three or more free radicals selected from the following 丨 to 3 free radicals of the Ministry of Economic Affairs, Central Bureau of Standardization, Beigong Consumer Cooperative Print 5.1 halogen atoms such as fluorine, chlorine, bromine or broken atoms, 5.2 CF3, 5.3 CH "S (0) y, -9. The paper size is not in accordance with Chinese National Standard (CNS) A 4 specifications (210X297 mm)

-裝 ί請先閲讀背面之:!i意事項再填窝本頁) .訂 A6 B6 經濟部中央標準局員Η消费合作杜印製 五、發明説明(8) 其中X為數字0,1或2, 5.4 R36-Wy 其中R36為氫原子,甲基或乙基,W為氧原子 ,NH或NCH3,且y為0或1, 5-5 CmF2m+1 > 5.6 p比p定基, 5.7喳啉基,或 5.8異喳啉基, Z為 1) -C0- 2) -CH2- ’ 3) -[CH(OH)]q_ 其中q為數字1,2或3, 4) -[C(CH3)(OH)]q-, 其中q為數字1,2或3, 5) -0- ’ 6) -NH-, -N-, 7) I ch3 8) -S(0)x-, 其中X為0,1或2, 9) -S〇2-NH-,或 — 10- .............................................卜.................:袭......................、町.....................線. (請先閲讀背面之注意事項再填寫本頁一 本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐) 9 五、發明説明( iO) ^S〇2»jj--Please read the back of the first page:! I will pay attention to the matter before filling the nest page). Order A6 B6 Printed by the member of the Central Standards Bureau of the Ministry of Economic Affairs and Consumer Cooperation V. Invention description (8) where X is the number 0, 1 or 2 , 5.4 R36-Wy where R36 is a hydrogen atom, methyl or ethyl, W is an oxygen atom, NH or NCH3, and y is 0 or 1, 5-5 CmF2m + 1 > 5.6 p vs p definite, 5.7 octaline Group, or 5.8 isodocinol group, Z is 1) -C0- 2) -CH2- '3)-[CH (OH)] q_ where q is the number 1, 2 or 3, 4)-[C (CH3) (OH)] q-, where q is the number 1, 2 or 3, 5) -0- '6) -NH-, -N-, 7) I ch3 8) -S (0) x-, where X is 0, 1 or 2, 9) -S〇2-NH-, or — 10- .................................... ............... Bu ....................: Attack .................. ....... 、 町 ..................... line. (Please read the precautions on the back before filling this page. A paper standard applies to China National Standard (CNS) A 4 specifications (210X297 mm) 9 V. Description of the invention (iO) ^ S〇2 »jj-

I 卜燒基, X如下列定義·· a) N或 b) C-R37 , )-烷基或Μ),基, 其中R37為氫原予,(c Y如下列定義: 】‘I Bu burning group, X is defined as follows · a) N or b) C-R37,) -alkyl or Μ), group, wherein R37 is a hydrogen atom, (c Y is defined as follows: ‘‘

a) NH b) -N- (c]-c6)〜烷基, c) —N~ (c2-c4)-缔基,或 d) r35-ch2N-z-, 5其中r35,11與2如g)項之定義, R R,R與尺相同或相里,五八s(4 a) 氫原子,且分別如下列定義 b) (C〗-C5)-烷基,直鏈或分支, c) 苯基 若取代基 R11,R12,R' r22,r23 25 Γ,r33,r3、r35含有-個或多個不對稱中V,R: 明涵盍主S及呈R組態之化合物。.化合物 非對映異構物,消祕或其混合物之料。h異構物 所定義之烷基可為直鏈或分支者。 較佳式I a,I b或I C化合物,及/或式J a,工&或J < 化合物之生理上可耐受鹽為式中R如下定義: ’ A6 B6 經濟部中央標準局員工消費合作杜印製 五、發明説明( ) I )式V自由基,式中R11如下列定義: a) 氟原子, b) 氯原子, R丨5 、 c) ,其中R14與R15如上述定義, R1 ‘ d) R13-S(0)n-,其中η為數字0,1或2,或 e) 苯氧基, 其中R12如下列定義: a) R13-S(0)n,其中η為零,1或2,或 R w b) 其中r14與R】5如上述定義,或 R15 Π)式VI自由基,式中R21,R22或R23如下列定義: a) 氫原子, b) 鹵原子,如··氟,氣或溴原子,或 c) (CrCJ-烷基, 其中一個R21,R22或R23取代基亦可代表 1) OH, 2) (q-C,)-烷氧基。 24 3) R -CnH2n-〇m, 其中m為數字0或1, η為數字0,1,2或3, —12 — ...........'i:.........:..................一........................裝......................訂.....................線 {請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)甲4规格(210x 297公釐) 五、發明説明( 11a) NH b) -N- (c) -c6) ~ alkyl, c) —N ~ (c2-c4) -alkenyl, or d) r35-ch2N-z-, 5 where r35, 11 and 2 are as Definition of item g), RR, R are the same as or in line with the ruler, five or eight s (4 a) hydrogen atoms, and as defined below b) (C〗 -C5) -alkyl, straight or branched, c) Phenyl if the substituents R11, R12, R 'r22, r23 25 Γ, r33, r3, r35 contain one or more asymmetric middle V, R: Ming Hanyu main S and compounds in R configuration. . Compounds Diastereomers, secretions or mixtures of them. The alkyl group as defined by h isomer may be linear or branched. Preferred compounds of formula I a, I b or IC, and / or formula J a, industrial & or J < physiologically tolerable salts of compounds are defined as R in the formula as follows: 'A6 B6 Employee of Central Bureau of Standards, Ministry of Economic Affairs Consumer Cooperation Du Printed V. Description of the invention () I) Formula V radicals, where R11 is defined as follows: a) Fluorine atom, b) Chlorine atom, R 丨 5, c), where R14 and R15 are as defined above, R1 'd) R13-S (0) n-, where η is the number 0, 1 or 2, or e) phenoxy, where R12 is as defined below: a) R13-S (0) n, where η is zero , 1 or 2, or R wb) where r14 and R] 5 are as defined above, or R15 Π) Formula VI radical, where R21, R22 or R23 are as defined below: a) hydrogen atom, b) halogen atom, such as ·· Fluorine, gas or bromine atom, or c) (CrCJ-alkyl, where one R21, R22 or R23 substituent can also represent 1) OH, 2) (qC,)-alkoxy. 24 3) R -CnH2n-〇m, where m is the number 0 or 1, η is the number 0, 1, 2 or 3, —12 — ..... '' i: .... ..................................................... ...................... order ............... line {please read the back first Please pay attention to this page and then fill out this page) This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210x 297 mm) V. Description of the invention (11

R24代表 υ CPp2p+1 其中P為數字1 ’恒必續 η為數字〇或],、 2) (c5-c7)-環烷基, 3) 苯基, 4) 吡啶基, 5) 喳啉基, 6) 異喳啉基, 其中自由基3)至6)中之^^ 自下列之基團取代:¥系未經取代或 3·1氟原子,3-2氯原子, 乂 3.3 CF3, 3·4 CH3,或 3·5甲氧基,或 m)式vii自由基’式中 a) 氨原子, b) 鹵原子,如··氟,氯,溴或碘原子,或 c) (C,-C6)-垸基,直鏈或分支,或 經一個選 r33或R34如下列定羲·· (請先W讀背面之注意事項再場寫本頁) -裝 訂. 線丨丨 經 濟 部 中 央 標 準 局 Μ 工 消 费 合 社 印 製 35 d) R ^ηΗ2η-Ζ- 其令n為數字Ο ’ 1或2,且亞乾基鍵-CnIi2n-為直鍵或分 支,且其中一個碳原子可被氧’硫或氮原子置換, R35為 13· 本紙張尺度適用⑽)>?4規格(2歌297公着) A6 B6 經濟部中央標準局員工消費合作社印製 五、發明説明(12)1) 氫原子, 2) (C5-C8)-環烷基,3) (C5-C8)-環烷基,係經一個羥基取代,或其中一 個亞甲基被氧,硫或氮原子置換,或4) 苯基,未經取代.或經1至3個選自下列之基團取代 • I4.1鹵原子,如:敦_,氯,溴或辨原子, 4.2 CF3, 4_3 CH3-S(0)x,其中X為數字〇,1或2, 4_4· R3、Wy .其中R36為氫原子,甲基或乙基,W為氧原子 ,NH或NCH3,且y為0或1, 4-5 CmF2m+1 -其中m為數字1,2或3,4.6 p比淀基,.4.7 σ奎淋基,或 4.8異喳啉基,Ζ為 1) -C0-, 2) -CH2-, 3) -[CH(OH)]q-,其中q為數字1,2或3, 4) -[C(CH3)(OH)]q-,其中q為數字 1,2或3 ; -14- 裝-.....................訂;...................線 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) A6 B6 五、發明説明(13) 5) 〜〇〜或 6) -S(〇)「, 其中X為〇,1或2, X如下列定義: a) Ν'或 .、 b) CH, Y如下列定義 a) -N-(cvc6)-烷基, b) ~N~(C2-C4)-稀基,或 c) R35CnH2n-Z—, 其中R ’ n與Z如d)項之定義, R R,R與r8相同或相異,且分別如下列定義 a) 風原子, b) (Ci~c5)-垸基,直鏈或分支。 特別佳之式I a,I b或I c化合物為 式中Ru如下列定義: -..........ΤΓ..................線 {請先閲讀背面之注意事項再填窝本頁)R24 represents υ CPp2p + 1 where P is the number 1 'the constant η is the number 〇 or], 2) (c5-c7) -cycloalkyl, 3) phenyl, 4) pyridyl, 5) octylinyl , 6) Isocinolinyl, in which radicals 3) to 6) are substituted from the following groups: ¥ is unsubstituted or 3 · 1 fluorine atom, 3-2 chlorine atom, and 3.3 CF3, 3 · 4 CH3, or 3 · 5 methoxy, or m) free radical of formula vii 'where a) an ammonia atom, b) a halogen atom, such as ·· fluorine, chlorine, bromine or iodine atom, or c) (C, -C6) -Emperor, straight chain or branch, or select r33 or R34 as follows: (Please read the precautions on the back before writing this page) -Binding. Thread 丨 丨 Ministry of Economic Affairs Central Standards Printed by Bureau M Industry and Consumer Corporation 35 d) R ^ ηΗ2η-Z- Let n be the number Ο '1 or 2, and the sub-dry bond -CnIi2n- is a straight bond or branch, and one of the carbon atoms can be oxygenated 'Sulfur or nitrogen atom replacement, R35 is 13 · This paper standard applies ⑽)> 4 specifications (2 songs 297 published) A6 B6 Printed by the employee consumer cooperative of the Central Bureau of Standards of the Ministry of Economy V. Description of invention (12) 1) Hydrogen atom, 2) (C5-C8) -cycloalkyl, 3) (C5-C8 ) -Cycloalkyl, substituted by a hydroxyl group, or one of the methylene groups is replaced by an oxygen, sulfur or nitrogen atom, or 4) Phenyl, unsubstituted. Or substituted by 1 to 3 groups selected from • I4.1 halogen atoms, such as: _, chlorine, bromine or discriminating atoms, 4.2 CF3, 4_3 CH3-S (0) x, where X is the number 〇, 1 or 2, 4_4 · R3, Wy. Where R36 is Hydrogen atom, methyl or ethyl, W is oxygen atom, NH or NCH3, and y is 0 or 1, 4-5 CmF2m + 1-where m is the number 1, 2 or 3, 4.6 p than the base, .4.7 σ quinolinyl, or 4.8 isocinolinyl, Z is 1) -C0-, 2) -CH2-, 3)-[CH (OH)] q-, where q is the number 1, 2 or 3, 4) -[C (CH3) (OH)] q-, where q is the number 1, 2 or 3; -14- Pack -..................... Order ; .................. line (please read the notes on the back before filling in this page) This paper size is applicable to the Chinese National Standard (CNS) A 4 specifications (210x297 C) A6 B6 5. Description of the invention (13) 5) ~ 〇 ~ or 6) -S (〇) ", where X is 〇, 1 or 2, X is defined as follows: a) Ν 'or., B) CH , Y is as defined below a) -N- (cvc6) -alkyl, b) ~ N ~ (C2-C4) -alkenyl, or c) R35CnH2n-Z—, where R'n and Z are as defined in item d), RR, R and r8 are the same or different, and are as defined below a) wind atom, b) (Ci ~ c5) -alkyl group, straight Chain or branch. Particularly preferred compounds of formula Ia, Ib or Ic are Ru in the formula as defined below: -......... ΤΓ .................. Line (Please read the precautions on the back before filling the nest page)

經濟部中央標準局員工消费合作社印製 其中R14與R15相同或相異,且分別代表下列定 1) 氫原子或 ^ 2) (CVC4)-烷基,或 R14與R15共同形成(C4-C7)-烷基鏈或 —15 — 本紙張尺度適用t國國家標準(CNS)甲4规格(210X297公釐) A6 _______ Β6 14、五、發明説明( ) 經濟部中央樣準局貝工消费合作杜印製 r13-s- 其中R13為 a) 苯基或 b) 對位經氯取代之苯基, 其中R12如下列定義: a) CH3-S〇2-, b) H2N-S〇2-, c) 苯氧基,或 d) 對位經氯取代之苯氧基, R5,R6 ’ R7與R8相同或相異,且分別如下列定義: a) 氫原子或 ' b) (C!-C4)~燒基, 及式I a,I b或I c化合物之生理上可耐受之鹽。 特別佳者為 曱基p朶羰基)-(胺基亞胺甲基)胺基]乙燒_1,1_ 雙膦酸四乙§旨,2-[(1-甲基-2-p引噪基羰基)_(胺基亞胺甲基) 胺基]乙烷-U-雙膦酸,24(3-甲磺醯基Μ-六氫吡啶苯甲醯 基)-(胺基亞胺甲基)胺基]乙纪_1,1~雙膦酸,2-[(3-甲績醯基― 4-六氫p比咬苯甲酿基Η胺基亞胺甲基)胺基]乙垸-1,1-雙膦 酸四乙酯,2-[(3,5-二氯苯甲醯基)-(胺基亞胺甲基)胺基]乙 烷-U-雙膦酸四乙酯’及2-[(3,5-二氣苯甲醯基)-(胺基亞胺 甲基)胺基]乙烷雙膦酸。 根據本發明化合物可依例如下列製法製備: 使式IV化合物 —16 — ^......................-玎..........................線 (請先閲讀背面之注意事項再塡寫本頁) 本化張尺度適用中國國家樣準(CNS)甲4规格(21〇Χ297公f) 五、發明説明(15 A6 B6Printed by the Staff Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs where R14 and R15 are the same or different and represent the following: 1) Hydrogen atom or ^ 2) (CVC4) -alkyl, or R14 and R15 are formed together (C4-C7) -Alkyl chain or -15 — This paper scale is applicable to the national standard (CNS) A4 specification (210X297 mm) of A paper. A6 _______ Β6 14. V. Description of invention () Central Indian Bureau of Economics, Ministry of Economic Affairs, Shell Industry Consumer Cooperation Du Duin R13-s- wherein R13 is a) phenyl or b) phenyl substituted with chlorine at the para position, wherein R12 is as defined below: a) CH3-S〇2-, b) H2N-S〇2-, c) Phenoxy, or d) phenoxy substituted with chlorine at the para position, R5, R6 'R7 and R8 are the same or different, and are as defined below: a) hydrogen atom or' b) (C! -C4) ~ Burn-in groups, and physiologically tolerable salts of compounds of formula Ia, Ib or Ic. Particularly preferred is methyl p-docarbonyl)-(aminoiminomethyl) amino] ethane-1,1_bisphosphonic acid tetraethyl § Purpose, 2-[(1-methyl-2-p noise Carbonyl) _ (aminoiminomethyl) amino] ethane-U-bisphosphonic acid, 24 (3-methanesulfonyl M-hexahydropyridinebenzyl)-(aminoiminomethyl ) Amino] ethane-1,1 ~ bisphosphonic acid, 2-[(3-methoxypyridyl-4-4-hydrogen p ratio benzyl H aminoaminoiminomethyl) amino] ethyl amine -1,1-bisphosphonic acid tetraethyl ester, 2-[(3,5-dichlorobenzyl)-(aminoiminomethyl) amino] ethane-U-bisphosphonic acid tetraethyl ester 'And 2-[(3,5-difluorobenzyl)-(aminoiminomethyl) amino] ethane bisphosphonic acid. The compound according to the present invention can be prepared according to, for example, the following preparation method: The compound of formula IV—16 — ^ ................................. ................... line (please read the precautions on the back before writing this page) This standard is applicable to China National Standards (CNS) A4 specifications ( 21〇Χ297 公 f) 5. Description of the invention (15 A6 B6

式中R,R6 ’ R7與R8如式I a之定義, a)與式m化合物於惰性溶劑之存在下反應Where R, R6 'R7 and R8 are as defined in formula I a, a) reacts with a compound of formula m in the presence of an inert solvent

經濟部中央標準局貝工消費合作社印製 產生式I a,I b或I c化合物,其中R11與R12如式I a,I b或I c中之定義,且若適當時, B) 使式I a,I b或I c化合物之雙膦酸酯轉化成相應之雙膦 酸,或 使式IV化合物,式中R5,R6,R7與R8如式I a之定義, C) 與式化合物於惰性溶劑之存在下反應nh2 -N — C == Ν Η (VIII) Η -17-Printed by the Beigong Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs to produce compounds of formula Ia, Ib or Ic, where R11 and R12 are as defined in formula Ia, Ib or Ic, and if appropriate, B) use formula The bisphosphonate of the compound I a, I b or I c is converted to the corresponding bisphosphonic acid, or the compound of formula IV, where R5, R6, R7 and R8 are as defined in formula I a, C) and the compound of formula Reaction in the presence of an inert solvent nh2 -N — C == Ν Η (VIII) Η -17-

本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐) 裝......................,可......................^ (請先閲讀背面之注意事項再填寫本頁)The size of this paper is in accordance with Chinese National Standard (CNS) Grade 4 (210X297mm) ........................., yes ... ............... ^ (Please read the notes on the back before filling out this page)

五、發明説明(16 產生式I a,I b或I C化合物,式中R21,尺22及尺23如式I a,I b或I c之定義,且若適當時, D) 使式I a,I b或I c化合物之雙膦酸酯轉化成相應之雙膦 酸,或 使式IV化合物,式中R5,R6,/與〆如式〗&中之定義 E) 與式IX化合物於惰性溶劑之存在下反麻 {請先閲讀背面之注意事項再填窝本頁)V. Description of the invention (16 produces compounds of formula Ia, Ib or IC, where R21, ruler 22 and ruler 23 are as defined in formula Ia, Ib or Ic, and if appropriate, D) use formula Ia , The bisphosphonate of the compound of I b or I c is converted into the corresponding bisphosphonic acid, or the compound of formula IV, where R5, R6, / and (as defined in formula〗 & E) and the compound of formula IX in Anti-numb in the presence of inert solvents (please read the precautions on the back before filling the nest page)

V II ο νη2C = ΝΗ 裝 ΗV II ο νη2C = ΝΗ installed Η

(I 訂 33與R34如 經濟部中央標準局貝工消费合作社印製 產生式la,lb或Ic化合物,式中r31,r32,r 式la’ I b或Ic中之定義,且若適當時, FH吏式I a,I b或I c化合物之雙膦酸酯轉化成相應之雙膦 酸。 製法A)項之最佳製程為使等莫耳量或至高過量三倍之 式in化合物,若適當時於惰性溶劑中如:二〒亞颯(dms〇) ,二甲基甲醯胺(腳)1苯’(Μ) —烷醇,四氫呋喃 (THF),二氧陸園或乙醚中,與式汉化合物,在添加鹼如 :碳酸钟,碳酸釣,氫氧化钟,三乙胺,二乙胺,或不添 加鹼下反應,產生式I 3,I 6或丨c化合物。反應溫度為 -18-(I order 33 and R34 as printed by the Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs to produce compounds of formula la, lb or Ic, where r31, r32, r are defined in formula la 'I b or Ic, and if appropriate, The bisphosphonate of the compound of formula Ia, Ib or Ic is converted into the corresponding bisphosphonate. The optimal process of item A) is to make the compound of formula in equal to the molar amount or three times the excess, if Where appropriate, in an inert solvent such as: dimethylamine (dms〇), dimethylformamide (foot) 1 benzene '(M)-alkanol, tetrahydrofuran (THF), dioxan or diethyl ether, and The compound of formula Han reacts with the addition of a base such as: carbonate, carbonate, hydroxide, triethylamine, diethylamine, or without the addition of a base to produce compounds of formula I 3, I 6 or 丨 c. The reaction temperature is -18-

本紙張尺度適用中國國家搮準(CNS)甲格(210x297公U ::ί)5537 Α6 Β6 經濟部中央標準局員工消費合作社印製 五、發明説明( ) 約25°c至100°C,且當使用溶劑時,以約25°C至溶劑沸點之 間溫度較佳,特定言之70°C。反應時間為6至48小時,以12 至24小時較佳。由例如薄層層析法決定反應是否完成。 單離及純化式I a,I b或I c化合物時,反應混合物 可於矽膠管柱上,使用例如··乙酸乙酯與醇(體積比6:1)之 溶離液混合物進行純化。所得之式I a,I b或I c化合物 可經水解作用轉化成相應之雙膦酸(製法B項),例如:於 濃鹽酸中回流加熱,或於無水溶劑中,以強酸或三甲石夕燒 基鹵化物處理後,進行水解。含無水氫溴酸之乙酸溶液可 直接使用或經過適當稀釋使用,或可使用三甲矽烷基碘溶 於如四氯甲烷,二甲基甲醯胺:氯仿或甲苯等溶劑中之溶 液。水解作用可冷卻或加熱進行,例如:S旨可與三甲碎燒 基鹵化物反應,同時在-ίο °c或以下溫度下冷卻,得到部 份水解產物。 製法A)項之起始物質,化合物瓜及IV可依文獻上已知 製法,以簡單方式製得(EP 0 298 553 ; EP 0 416 499)。 製法C)項之最佳製程為使等莫耳量或至高過量三倍之 式vm化合物,若適當時於惰性溶劑中如:二甲亞颯(dmso) ,二甲基甲醯胺(DMF),甲苯,-烷醇,四氫呋喃 (THF),二氧陸圜或乙醚中,與式IV化合物,在添加鹼如 •碳酸鉀,碳酸鈉,氫氧化鉀,三乙胺,二乙胺,或不添 加驗下反應,產生式I a,I b或I C化合物。反應溫度為 约25°C至l〇〇°C,且當使用溶劑時,以約25°C至溶劑沸點之 間溫度較佳,特定言之70°C。反應時間為6至48小時,以12 -19- 裝.......................可.....................線 (請先閲讀背面之注意事項再填寫本頁~ 本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐) A6 B6 五、發明説明(iS) 至24小時較佳。由例如薄層層析法決定反應是否完成。 單離及純化式I a,I b或I c化合物時,反應混合物 可於ί夕膠管柱上,使用例如:乙酸乙醋與醇(體積比6:1)之 溶離液混合物進行純化。所得之式I a,I b或I c化合物 可經水解作用轉化成相應之雙膦酸(製法D項),例如:於 濃鹽酸中回流加熱,或於無水溶劑中,以強酸或三甲矽烷 基鹵化物處理後,進行水解。含無水氫溴酸之乙酸溶液可 直接使用或經過適當稀釋使用,或可使用三甲矽烷基碘溶 於如四氯甲烷,二甲基甲醯胺,氣仿或甲苯等溶劑中之溶 液。水解作用可冷卻或加熱進行,例如:酯可與三甲矽烷 基鹵化物反應,同時在-10 °C·^以下溫度下冷卻,得到部 份水解產物。 製法C)項之起始物質,化合物IV可依文獻上已知製法 ,以簡單方式製得(EP 0 298 553 ; EP 0 416 499)。 式化合物可由式Π化合物This paper scale is applicable to the Chinese National Standard (CNS) Grade A (210x297 g U :: ί) 5537 Α6 Β6 Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy V. Description of invention () Approximately 25 ° C to 100 ° C, and When a solvent is used, a temperature between about 25 ° C and the boiling point of the solvent is preferred, specifically 70 ° C. The reaction time is 6 to 48 hours, preferably 12 to 24 hours. Whether the reaction is completed is determined by, for example, thin layer chromatography. When isolating and purifying compounds of formula Ia, Ib or Ic, the reaction mixture can be purified on a silica gel column using, for example, a mixture of eluents of ethyl acetate and alcohol (volume ratio 6: 1). The resulting compound of formula Ia, Ib or Ic can be converted into the corresponding bisphosphonic acid by hydrolysis (item B), for example: refluxing in concentrated hydrochloric acid, or in an anhydrous solvent, with strong acid or trimethyl silicate After the alkyl halide treatment, hydrolysis is carried out. The acetic acid solution containing anhydrous hydrobromic acid can be used directly or after appropriate dilution, or a solution of trimethylsilyl iodide in a solvent such as tetrachloromethane, dimethylformamide: chloroform or toluene can be used. Hydrolysis can be carried out by cooling or heating. For example, S can be reacted with trimethyl pyrocalyl halide while being cooled at a temperature of -10 ° C or below to obtain a partial hydrolysate. The starting materials of the preparation method A), the compounds melon and IV can be prepared in a simple manner according to the preparation methods known in the literature (EP 0 298 553; EP 0 416 499). The best process of the method C) is to make the compound of formula vm with an equivalent molar amount or a three-fold excess, if appropriate in an inert solvent, such as: dimethyl sulfa (dmso), dimethylformamide (DMF) , Toluene, -alkanol, tetrahydrofuran (THF), dioxan or ether, with the compound of formula IV, in the addition of bases such as potassium carbonate, sodium carbonate, potassium hydroxide, triethylamine, diethylamine, or not Adding the assay reaction produces compounds of formula Ia, Ib or IC. The reaction temperature is about 25 ° C to 100 ° C, and when a solvent is used, the temperature is preferably about 25 ° C to the boiling point of the solvent, specifically 70 ° C. The reaction time is 6 to 48 hours, packed in 12-19 -................................................. ......... Line (please read the precautions on the back before filling in this page ~ This paper size is applicable to the Chinese National Standard (CNS) A4 specifications (210X297 mm) A6 B6 V. Invention description (iS) It is preferably up to 24 hours. For example, thin-layer chromatography determines whether the reaction is complete. When isolating and purifying the compounds of formula Ia, Ib, or Ic, the reaction mixture can be placed on a Glue column, using, for example, ethyl acetate It is purified with a dissolution mixture of alcohol (volume ratio 6: 1). The resulting compound of formula Ia, Ib or Ic can be converted into the corresponding bisphosphonic acid by hydrolysis (item D), for example: in concentrated hydrochloric acid Heated at medium reflux, or treated with strong acid or trimethylsilyl halide in an anhydrous solvent, and then hydrolyzed. The acetic acid solution containing anhydrous hydrobromic acid can be used directly or after appropriate dilution, or it can be dissolved using trimethylsilyl iodide Such as a solution in solvents such as tetrachloromethane, dimethylformamide, gasform, or toluene. Hydrolysis can be carried out by cooling or heating, for example: ester can be combined with trimethylsilyl Compound reaction, while cooling at a temperature below -10 ° C · ^, to obtain a partial hydrolysate. Preparation method C) The starting material, compound IV can be prepared in a simple manner according to the preparation method known in the literature (EP 0 298 553; EP 0 416 499). The compound of formula

0 裝......................訂.....................線 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局貝工消费合作社印製 與胍反應製備,其中R1至R3如上述定義,且L為容易進行 親核性取代作用之釋離基。 式Π活化酸衍生物,式中L為烷氧基,以甲氧基,苯 — 20- 本紙張尺度適用中國國家標準(CNS)甲4规格(210x297公釐) 經濟部中夬標準局貝工消费合作社印製 A6 B6 五、發明説明(19) 氧基車乂佳’笨疏基’甲硫基,2K硫基,氮雜環,以卜 米坐基較佳宜依本身已知之方式,由其基礎之羰基氯( 式Π,L=C1)製備,後者則由其基礎之羧酸(式Π,L=〇H), 依本身已知之方式製備,例如:與亞硫醯氣反應。除了式 π複基氯α=α)外,亦可、製備其他式Π活化酸衍生物,其 係依本身,知方式’直接由其基礎之苯甲酸衍生物(式Π ’ L=0H)製備’如,例如:製備式Π之甲酯,L=〇CH3時, 係經 HC1氣體之曱醇溶液處理,製備式Π咪唑化物 (imidazolide)時’以羰基二咪唑處理(η —咪唑基,史塔(staab), Angew, Chem. lnt. Ed Engl,丨,别―367(1962)),製備混合酸纤 Π時’於二乙胺之存在下.,在惰性溶劑中,以 C1-C〇(X:2H5或甲苯磺醯氯處理,及苯甲酸之活化作用,係 以二環己基碳化二亞胺(DCC)或以〇_[(氰基(乙氧羰基)亞甲 基)胺基]-U,3,3-四甲基糖醛繪四氟硼酸鹽(__τοτυ")處理(威 斯與克洛莫(Weiss and Krommer),Chemiker Zeitung 98, 817(1974)] 。許多適合製備式Π之活化羧酸衍生物之方法説明於j.馬 奇之咼級有機化學,第3版(強威利父子出版社,1985)(J. March, Advanced Organic Chemistry, Third Edition (John Wiley & Sons, l985)第35〇頁,其中指出文獻出處。 式Π活化叛酸衍生物與胍之反應係依本身已知方式, 於質子性或非質子性極性,但惰性之有機溶劑中進行。有 關此點,己證實甲醇或THF在2〇°C至此等溶劑之沸點間之 溫度下,適用於苯甲酸甲酯(Π,L=OMe)與胍之反應。大 多數化合物E與非鹽型之胍宜在非質子性惰性溶劑,如: -21 - .......................................................................................裝..............tr.......................線 {請先閲讀背面之注意事項再填窝本頁) 本紙張尺度適用中國國家橒準(CNS)甲4规格(210x 297公梦) A60 Pack .................... Order ............... Thread (please first Read the notes on the back and fill in this page) Printed by the Peking Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs and prepared by reaction with guanidine, where R1 to R3 are as defined above, and L is a free radical for easy nucleophilic substitution. Activated acid derivative of formula Π, where L is alkoxy, methoxy, benzene-20- This paper scale is applicable to China National Standard (CNS) A 4 specifications (210x297 mm). Printed by the consumer cooperative A6 B6 V. Description of the invention (19) Oxycarabine 'Benshuyl' methylthio, 2K thio, nitrogen heterocycle, preferably based on the method known per se The basic carbonyl chloride (formula Π, L = C1) is prepared, and the latter is prepared from the basic carboxylic acid (formula Π, L = 〇H) in a manner known per se, for example, by reacting with sulfite gas. In addition to formula π complexyl chloride (α = α), other activated acid derivatives of formula Π can also be prepared, which are prepared directly from their basic benzoic acid derivatives (formula Π 'L = 0H) in a known way 'For example, when preparing methyl ester of formula Π, when L = 〇CH3, it is treated with methanol solution of HC1 gas, when preparing formula Π imidazolide (imidazolide)' is treated with carbonyl diimidazole (η-imidazolyl, history Tower (staab), Angew, Chem. Lnt. Ed Engl, 丨, Be-367 (1962)), in the preparation of mixed acid fiber Π 'in the presence of diethylamine. In an inert solvent, with C1-C〇 (X: 2H5 or toluenesulfonyl chloride treatment, and the activation of benzoic acid, with dicyclohexylcarbodiimide (DCC) or with 0 _ [(cyano (ethoxycarbonyl) methylene) amine] -U, 3,3-tetramethyl uraldehyde painted tetrafluoroborate (__τοτυ ") treatment (Weiss and Krommer, Chemiker Zeitung 98, 817 (1974)]. Many are suitable for the preparation of formula Π The method of activating carboxylic acid derivatives is described in J. March's 咼 级 organic chemistry, 3rd Edition (Qianweili Father and Son Press, 1985) (J. March, Advanced Organic Chemistry, T hird Edition (John Wiley & Sons, l985) page 35, which indicates the source of the document. The reaction of the formula II activated retinoic acid derivative with guanidine is in a protonic or aprotic polarity, but inert, in a manner known per se In organic solvents. At this point, it has been confirmed that methanol or THF is suitable for the reaction of methyl benzoate (Π, L = OMe) with guanidine at a temperature between 20 ° C and the boiling point of these solvents. Most Compound E and non-salt guanidine should be in aprotic inert solvents, such as: -21-............................. .................................................. ........ installed .............. tr .......................... line {please Please read the precautions on the back before filling in this page.) The paper size is suitable for China National Standard (CNS) Grade 4 (210x 297 Gongmeng) A6

經濟部中央標準局貞工消费合作社印製 THF,二甲氧乙:^二氧陸圜中進行。然而,當π之反應 中使用如,例如·統化蚁㈣’树仙水作為溶劑 0 若L--C1時,宜添加酸吸收劑,例如:以過量胍之形 ,結合氫齒酸。 .、 有些式Π鹼性苯甲酸衍生物係已知者且述於文獻中。 已知之式Π化合物可依文獻上已知之方法製備。 式Π之叛奴或其醋(例如:.L=—〇H或—〇_曱基),其中 R為鹵素或R為石肖基,為多用途之起始化合物,可用未合 成其他式Π羧酸,其中R2位置上之由素很容易依本身已知 方式,被許多種種親核性試劑如:苯酚,或醇 R4-CnH2n-OH或其驗金屬鹽置換,形成相應之苯甲酸衍生 物。硝基同樣地可在還原成相應之胺基苯甲酸後,經由山 邁德(Sandmeier)或烏曼(Ulmann)反應,形成所需之化合物, 特定言之’經_素取代之苯甲酸衍生物。許多情形下,亦 可依本身已知方式,使用弗立德-克拉弗特(Friedel-Crafts)觸 媒進行直接函化作用,將氣,漠或決引入特定之苯甲酸中 〇 製法E)項之最佳製程為使等莫耳量或至高過量三倍之 式JX化合物,若適當時於惰性溶劍中如:二甲亞颯(DMSO) ,二甲基甲醯胺(DMF),甲苯,(CrC4)-烷醇,四氫呋喃 (THF),二氧陸圜或乙醚中’與式IV化合物,在添加鹼如 :破酸却’碳酸納,氫氧化钾’三乙胺,二乙胺,或不添 加鹼下反應,產生式I a,I b或I C化合物。反應溫度為 一 22- 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公度7 (請先閲讀背面之注意事項再填寫本頁} .裝 *^τ 五、發明説明( 五、發明説明( 經濟部中央標準局貝工消费合作社印製 社且當使用溶劑·,以約25°c至溶劑沸點之 間>皿度較佳,特定言之7{rc。反應時間為6至48小時,以12 纽::時較佳。㈣如薄層騎法決定反應是否完成。 可於化式1 a,1 6或1 ^化合物時,反應混合物 1雜、、二柱上,使用例如··乙酸乙醋輿醇(體積比6··1)之 洛離^ θ物進行純化。所得之式〗a,〗。化合物 解作用轉化成相應之雙膦酸(製法呼),例如:於濃 ΐίΐΓ沉加熱,或於無水溶劑中’以強酸或三甲雜基 里後,進行水解。含無水氫漠酸之乙酸溶液可直 接使用或經過適當稀釋使用,或可使用三甲残基辦溶於 如四氯m基甲醯胺1仿或甲苯等溶劑中^溶液 水解作用可冷卻或加熱進行,例如:酯可與三甲矽烷基 _化物反應,同時在_1glxt溫度τ 水解產物。 行巧I切 、製,Ε)項之起始物質,化合物贝可依文獻上已知製法 以簡單方式製得(ΕΡ 〇 298 553 ; £Ρ 0 416 499)。 式Κ化合物可依已知方式製備(DE 43 26 〇〇55)。 .本發明亦有關含有至少有效量之至少一種式j a、工b 或I c化合物與/或式j a、j卜或〗。化合物之生理上接受之 |及酱藥上適合,且生理上可耐受之輔助物質及賦形劑 ,稀釋劑與/或其他活性物質。 , 本發明尚有關以式Ia、113或1(;化合物與/或其生理 上可耐受之鹽,於生產預防及治療骨骼系統變質性病 藥物上之用法。 23 (請先閲讀背面之注意事項再蜞寫本頁一 .裝 .訂 -線. 本紙張尺度適財國國Η規格m〇X297公龙) A6 B6 22' 五、發明説明( 本發明亦有關式h、IbiUc化合物與/或其生理上 可耐文(鹽於生產治療與骨再吸收作用提高之病變定 ^轉移性骨癌’柏哲德氏症’高_血症或骨疏鬆症之藥 物上之用法。 根據本發明之藥物可經皮表,經皮膚,鼻内,靜脈内 ’肌内’腹膜内’皮τ ’動脈内,周邊動脈,直腸内或經 口投與。 供預防及治療骨疏鬆症之根據本發明藥物之生產係由 至少一種式1 a、ΪΙϊ或Ic化合物與/或其一種生理上可耐 文,若適當時與輔助物質及/或賦形劑共同轉化成合 適劑量形式。輔助物質及賦形趔衍生自載劑,防腐劑,及 其他習知之輔助物質之族群中。 式I a、I b或I c化合物在此情形下可單獨使用,或 與醫藥上輔助物質共同使用,特定言之用於獸醫學及人類 醫學上。 適合所需醫藥調配物之輔助物質為相關技藝專家們根 據其專業知識習知者。除了溶劑,凝膠形成劑,栓劑基質 ’鍵劑輔助物質及其他活性物質載劑外,亦可使用例如: 抗氧化劑’分散劑’乳化劑,消泡劑’香料,防腐劑,溶 解劑或色素。 供口服之形式係混合活性化合物及適合此目的之添加 物’如,賦形劑,安定劑或惰性稀釋劑,並依習知方法轉 化成合適之劑量形式如:錠劑,包衣錠劑,硬明膠囊,水 性’醇類或油性溶液。可使用之惰性載劑實例為阿拉伯膠 24- .....................................................................................裝......................訂.....................線… (請先閲讀背面之注意事項再填窝本頁) 經濟部t夬標準局員工消費合作社印製 私紙張尺度適用家標毕甲4规格mQx297^^) A6 B6 經濟部中央標準局貝工消费合作社印製 五、發明説明(1 ,氧化鎂,碳酸鍰,磷酸钾,乳糖,葡萄糖或殿物,尤指 玉米澱粉。此類製法之製品可呈乾顆粒及濕顆粒。合適之 油性賦形劑或溶劑實例為植物油或動物油,如莫花油或魚 肝油。 供皮下或靜脈内投藥時,若需要時,可使用此目的習 用之物質如:溶解劑,乳化劑或其他輔助物質,將活性化 合物轉化成溶液,懸浮液或乳液。合適溶劑實例為:水, 生理食鹽水或醇,例如:乙醇、丙醇、甘油,及糖溶液, 如:葡萄糖或甘露糖醇溶液,或上述各種溶劑之混合物。 適合呈氣溶膠或喷液形式投藥之醫藥調配物實例為式 I a、I b或I C活性物質含於攀藥上可接受之溶劑如,特 定言之乙醇或水,或此等溶劑之混合物中之溶液,懸浮液 或乳液。若需要時,調配物亦可包含其他醫藥輔助物質如 :界面活性劑,乳化劑與安定劑,及推進劑氣體。此類製 品中活性物質含量濃度通常為0.1至10,特定言之0.3至3重 量%。劑氣體。此類製品中活性物質含量濃度通常為0.1至10 ,特定言之0.3至3重量%。 式I a、I b或I c活性物質之投藥劑量及投藥頻率端 賴所採用化合物之藥效及作用期長短而定;尚依待治療病 症之性質及嚴重性,及待治療之哺乳動物或人類之性別, 年齡,體重及個別反應而定。 根據本發明藥物之使用劑量依許多因素而定,如:藥 物之劑量形式,患者病變之病症,體重及嚴重性。然而每 曰約5000毫克。根據本發明藥物之劑量僅應暫時地超量。 -25- 裝......................訂.....................線 (請先閲讀背面之注意事項再填窝本頁) 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐)Printing of THF by the Zhengong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs, Dimethoxyethane: ^ Dioxo Luzhong. However, when the reaction of π is used, for example, as a solvent, for example, the integrated ant's tree fairy water 0. If L--C1, it is advisable to add an acid absorbent, for example, in the form of excess guanidine, combined with hydrogen acid. .. Some basic benzoic acid derivatives of formula II are known and described in the literature. Known compounds of formula Π can be prepared according to methods known in the literature. The traitor of formula Π or its vinegar (for example: .L = —〇H or —〇_ 曱 基), where R is halogen or R is schottky, is a versatile starting compound, other formula carboxylic acids can be used without synthesis Among them, the element in the R2 position is easily replaced by many kinds of nucleophilic reagents such as phenol, or the alcohol R4-CnH2n-OH or its metal-detecting salt in a manner known per se to form the corresponding benzoic acid derivatives. Nitro can also be reduced to the corresponding amino benzoic acid, through the Sandmeier or Ulmann reaction, to form the desired compound, in particular, the benzoic acid derivative substituted by . In many cases, Friedel-Crafts catalysts can also be used for direct functionalization in a manner known per se to introduce gas, gas, or water into specific benzoic acid. Method E) The best process is to make the compound of formula JX equal to a molar amount or a three-fold excess, if appropriate in an inert sword such as: dimethyl sulfoxide (DMSO), dimethyl formamide (DMF), toluene, (CrC4) -alkanol, tetrahydrofuran (THF), dioxan or ether, and the compound of formula IV, with the addition of alkali such as: acid breaking but sodium carbonate, potassium hydroxide, triethylamine, diethylamine, or The reaction without addition of base produces compounds of formula Ia, Ib or IC. The reaction temperature is 22-This paper scale is applicable to the Chinese National Standard (CNS) A 4 specifications (210x297 degrees 7 (please read the precautions on the back and then fill out this page). 装 * ^ τ Fifth, invention description (fifth, invention Description (printed by the Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs and when using a solvent, at a temperature between about 25 ° C and the boiling point of the solvent), preferably at a temperature of 7 {rc. The reaction time is 6 to 48 Hours, with 12 buttons :: time is better. (Iv) Determine whether the reaction is complete if the thin layer riding method can be used on the reaction mixture 1 and 2 columns when using compounds of formula 1 a, 16 or 1 ^, for example · Ethyl acetate and alcohol (volume ratio: 6 ·· 1) are purified by the separation of the compounds. The resulting formula is a,〗. The decomposition of the compound is converted into the corresponding bisphosphonic acid (preparation method), for example: Yu Con After heating, or after using strong acid or trimethylheteroyl in an anhydrous solvent, hydrolyze it. The acetic acid solution containing anhydrous hydrodesic acid can be used directly or after appropriate dilution, or it can be dissolved in trimethyl residues such as 4 Chloromethylformamide 1 imitation or toluene and other solvents ^ solution hydrolysis can be cold Or heating, for example: the ester can react with the trimethylsilyl compound, while hydrolysing the product at a temperature of _1glxt. The starting material is prepared by Qiao I cut, prepared, item E), the compound Bei Ke can be prepared according to known methods in the literature. It is prepared in a simple manner (ΕΡ 〇298 553; £ Ρ 0 416 499). The compound of formula K can be prepared in a known manner (DE 43 26 〇〇55). The present invention also relates to containing at least an effective amount of at least one formula ja, Worker b or I c compound and / or formula ja, j or b. Physiologically acceptable compounds and auxiliary substances and excipients, diluents and / or other that are physiologically acceptable and physiologically tolerable Active substances. The present invention also relates to the use of formula Ia, 113 or 1 (; compounds and / or their physiologically tolerable salts in the production of drugs for the prevention and treatment of degenerative diseases of the skeletal system. 23 (Please read the back Please note this page again. Binding. Binding-line. The paper size is suitable for the country's Η specifications m〇X297 male dragon) A6 B6 22 '5. Description of the invention (The present invention also relates to compounds of formula h, IbiUc and / Or its physiologically tolerable (salt can be used in production treatment and bone resorption The pathological determination of ^ metastatic bone cancer 'Bertrand's disease' hyper-emia or osteoporosis drug use. The drug according to the present invention can be percutaneously, transdermally, intranasally, intravenously 'intramuscularly 'Intraperitoneal' skin τ 'intra-arterial, peripheral arterial, intrarectal or oral administration. The production of the medicament according to the present invention for the prevention and treatment of osteoporosis consists of at least one compound of formula 1a, ΪΙϊ or Ic and / or It is a physiologically tolerant substance and, if appropriate, is converted into a suitable dosage form together with auxiliary substances and / or excipients. Auxiliary substances and excipients are derived from the group of carriers, preservatives, and other conventional auxiliary substances . The compounds of formula Ia, Ib or Ic can be used alone or in combination with medical auxiliary substances in this case, specifically in veterinary medicine and human medicine. The auxiliary substances suitable for the required pharmaceutical preparations are those of the relevant technical experts based on their professional knowledge. In addition to solvents, gel formers, suppository bases, 'bonding agent auxiliary substances, and other active substance carriers, for example, antioxidants' dispersants 'emulsifiers, antifoaming agents' fragrances, preservatives, dissolving agents or pigments can also be used . The form for oral administration is a mixture of active compounds and additives suitable for this purpose, such as excipients, stabilizers, or inert diluents, and converted into suitable dosage forms such as tablets, coated tablets, according to conventional methods Hard gelatin capsules, aqueous' alcoholic or oily solutions. An example of an inert carrier that can be used is gum arabic 24 --.......................................... ............................................. installation .. .................................................. line ... (please read the back page first Matters needing attention and refill this page) The standard of private paper printed by the Employee Consumer Cooperative of the Ministry of Economic Affairs of the Ministry of Economic Affairs is applicable to the home standard Bijia 4 specifications mQx297 ^^) A6 B6 Printed by the Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy (1. Magnesium oxide, sulfonium carbonate, potassium phosphate, lactose, dextrose or dextrose, especially corn starch. The products of such preparation methods can be dry granules and wet granules. Examples of suitable oily excipients or solvents are vegetable oil or animal oil , Such as Mohua oil or cod liver oil. For subcutaneous or intravenous administration, if necessary, the substances used for this purpose such as: dissolving agents, emulsifiers or other auxiliary substances can be used to convert the active compound into a solution, suspension or emulsion Examples of suitable solvents are: water, physiological saline or alcohols, such as ethanol, propanol, glycerin, and sugar solutions, such as glucose or mannitol solutions, Mixtures of the above-mentioned solvents. Examples of pharmaceutical formulations suitable for administration in the form of aerosols or sprays are active substances of formula Ia, Ib or IC contained in a pharmaceutical acceptable solvent such as ethanol or water in specific terms, or Solutions, suspensions or emulsions in a mixture of these solvents. If necessary, the formulation may also contain other medical auxiliary substances such as surfactants, emulsifiers and stabilizers, and propellant gases. Active substances in such products The content concentration is usually 0.1 to 10, specifically 0.3 to 3% by weight. Agent gas. The content concentration of the active substance in such products is usually 0.1 to 10, specifically 0.3 to 3% by weight. Formula I a, I b or I c The dosage and frequency of administration of the active substance depends on the efficacy and duration of the compound used; it also depends on the nature and severity of the condition to be treated, and the sex, age and weight of the mammal or human being to be treated The dosage depends on many factors, such as the dosage form of the drug, the pathological condition of the patient, body weight and severity. However, about 5000 per day Gram. The dose of the drug according to the present invention should only be temporarily exceeded. -25- Pack ..................... Order ... ............. Line (please read the precautions on the back before filling the nest page) This paper size is applicable to China National Standard (CNS) A 4 specifications (210x297 mm)

發明說明( 經濟部中夬標準局貝工消费合作杜印製 對體重7〇公斤之人類而言,每曰劑量為1〇至25〇〇毫克較 彻根據本發明藥物之每日劑量投藥方式—次投藥或分 個小劑量投藥。每天投藥3至8次較佳。 下列貫例更詳細説明本發明。除非另外説明 八 比數據係指體積%。 ., 乃 實例1 、2-[(3—甲磺醯基_4_六氫吡啶苯甲醯基H胺基亞胺甲基 胺基]乙烷-U-雙膦酸四乙酯之製法 土 使3·24克(10毫莫耳)(3-甲磺醯基_4_六氫吡啶基苯甲醯 基)-(胺基亞胺甲基)胺及3.0克(1Q毫莫耳)乙缔基二膦酸四乙 酯溶於4〇毫升無水四氫呋喃中。在其中添加〇5克(3.6毫莫 耳)無水碳酸鉀,混合物在保護性氣體下加熱至沸騰小 時。隨後再添加0·33克(2·4毫莫耳)碳酸鉀,混合物繼績^ 熱至沸騰2小時。反應混合物繼續於室溫下授拌丨6小時。 過濾及排除溶劑,產生4.5克粗物質,物質於妙膠管柱上層 析。所採用之溶離液為含10%乙醇之乙醇之乙酸乙酷。 收量:3.2克(理論値之52%) 曰Description of the invention (printed by the Beigong Consumer Cooperation Department of the China Bureau of Standards, Ministry of Economic Affairs. For humans weighing 70 kg, the daily dose is 10 to 25,000 mg. It is more consistent with the daily dose of the drug according to the present invention. The drug is administered twice or divided into small doses. It is better to administer 3 to 8 times a day. The following examples illustrate the present invention in more detail. Unless otherwise stated, the eight ratio data refers to the volume%., Is Example 1, 2-[(3- Preparation method of mesylate_4_hexahydropyridinebenzyl Haminoiminemethylamino] ethane-U-bisphosphonic acid tetraethyl ester 3.24 g (10 mmol) ( 3-Methanesulfonyl_4_hexahydropyridylbenzyl)-(aminoiminomethyl) amine and 3.0 g (1Q mmol) of tetraethylethenediphosphonate dissolved in 4 ML of anhydrous tetrahydrofuran. To this was added 0.5 g (3.6 mmol) of anhydrous potassium carbonate, and the mixture was heated to boiling hours under a protective gas. Subsequently, 0.33 g (2.4 mmol) of potassium carbonate was added, The mixture was heated to boiling for 2 hours. The reaction mixture continued to be stirred at room temperature for 6 hours. Filtration and removal of the solvent produced 4.5 g of crude material. . Analysis of the upper gel column using the eluent containing 10% of ethanol, acetic acid acetic cool ethanol Yield: 3.2 g (52% of theory Zhi) said

熔點:148至152°C 31P-NMR光譜: (CDCl3)5P=21.77ppm 實例2 2-[(3-甲績醯基-4-六氫吡哫苯甲醯基卜(胺基亞胺甲基) 26, ............................................................................................................、11............ ί犄先W讀背面之注意事項再填窝本頁) i紙張尺度通用t a ϋ家標$(cns丨甲4规格(21Gx297公爱了 *" " ---------------—一 — A6 B6 經濟部中央標準局®:工消费合作社印製 五、發明説明( 胺基]乙烷-1,1-雙膦酸之製法 使來自實例1之1.5克(2.4毫莫耳)2-[(3-甲磺醯基-4-六 氫吡啶苯甲醯基)-(胺基亞胺甲基)胺基]乙烷-1,1-雙膦酸四 乙酯溶於60毫升60°C之無水二氧陸圜中。反應混合物隨後 任其回到室溫,添加1.64克(10.8毫莫耳)溴三甲基矽烷。混 合物於室溫下攪拌16小時,隨後於60°C下加熱4小時。於40 °C /0.1鐸下排除溶劑及揮發性物質。然後添加15毫升水至 殘質中,混合物於室溫下攪拌4小時。所得殘質過濾,以 乙醇洗滌數次。所得殘質續於20毫升甲醇及10毫升水中煮 滞。 收量:460克(理論値之38%) *r,.Melting point: 148 to 152 ° C 31P-NMR spectrum: (CDCl3) 5P = 21.77ppm Example 2 2-[(3-Methacryl-4-hexahydropyridine-benzylamide (aminoiminomethyl ) 26, ............................................... .................................................. ..........., 11 ............ ί 犄 first read the precautions on the back and then fill this page) i paper standard universal ta ϋ home standard $ ( cns 丨 A4 specifications (21Gx297 public love * " " ----------------- 一 — A6 B6 Central Standards Bureau of the Ministry of Economic Affairs®: Printed by Industrial and Consumer Cooperatives V. Inventions Explain the preparation method of (amino) ethane-1,1-bisphosphonic acid so that 1.5 g (2.4 mmol) of 2-[(3-methanesulfonyl-4-hexahydropyridinebenzylamide from Example 1) )-(Aminoiminomethyl) amino] ethane-1,1-bisphosphonic acid tetraethyl ester was dissolved in 60 ml of anhydrous dioxane at 60 ° C. The reaction mixture was then allowed to return to room temperature , 1.64 g (10.8 mmol) of bromotrimethylsilane was added. The mixture was stirred at room temperature for 16 hours and then heated at 60 ° C for 4 hours. The solvent and volatile substances were removed at 40 ° C / 0.1 ° C. Then add 15 ml of water to the residue, The mixture was stirred at room temperature for 4 hours. The resulting residue was filtered and washed several times with ethanol. The resulting residue was boiled in 20 ml of methanol and 10 ml of water. Yield: 460 g (38% of theory) * r, .

溶點:209°C 31P-NMR光譜:(Na0D/D20)19.13ppm 實例3 2-[(3,5-二氯苯甲醯基)-(胺基亞胺甲基)胺基]乙烷-U-雙膦酸四乙酯之製法 使650毫克(2.4毫莫耳)(3,5-二氯苯甲醯基)-(胺基亞胺甲 基)胺及730毫克(2.4毫莫耳)乙烯基二膦酸四乙酯溶於30毫 升甲苯及6毫升二甲基甲醯胺(DMF)中。在其中添加0.17克(2.4 毫莫耳)無水碳酸钾,混合物加熱至滞騰21小時。反應溶 液隨後過濾,於旋轉蒸發器中濃縮。得到1.8克粗產物。物 質於攻膠管柱上純化。使用丙醇為溶離液。 收量:450毫克(理論値之35%) -27- ..................-:..............................................................裝.........ΤΓ線 {請先閲讀背面之注意事項再填寫本頁) 本紙張尺度遑用t國國家標準(CNS)甲4规格(210X297公釐) 295587 A6 B6 經濟部中央標準局貝工消費合作社印製 五、發明説明(26 ) 熔點:146至149°C 31P_NMR 光譜: (CDCl3)21_73ppm實例4 、 2-[(3,5-二氯苯甲醯基)-(胺基亞胺甲基)胺基]乙烷-1,1-雙膦酸之製法 使350毫克(0.62毫莫耳)2-[(3,5-二氣苯甲醯基)-(胺基亞 胺甲基)胺基]乙烷-U-雙膦酸四乙酯溶於20毫升乙腈中。 於氬氣下,在其中添加0.3克碘化鈉及0.41毫升(3.10毫莫耳) 溴二甲矽烷。混合物於室溫下標拌16小時,然後於40°C下 攪拌1小時。隨後過濾所形成之溴化鈉,母液在40 °C/0.1鐸 下排除溶劑及揮發性物質。添加20毫升二氯甲烷至殘質中 ,再次抽吸過濾所形成之固體。於40 °C /0.1鐸下排除二氯 甲燒。隨後添加15毫升水,混合物於室溫下檀拌15分鐘。 於60°C/12鐸下排除水。添加10毫升異丙醇至所得殘質中, 添加約1至2毫升水。混合物加熱5分鐘。冷卻後,抽吸過 濾無色晶體,於12鐸下眞空乾燥。 收量:170毫克(60%) 熔點:267°C 31P-NMR 光譜: (Na0D/D20)<5 31P=19.09ppm iH-NMR光譜: 一 28- ^......................-玎.....................線 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) A6Melting point: 209 ° C 31P-NMR spectrum: (Na0D / D20) 19.13ppm Example 3 2-[(3,5-dichlorobenzyl)-(aminoiminomethyl) amino] ethane- U-bisphosphonic acid tetraethyl ester is prepared by making 650 mg (2.4 mmol) (3,5-dichlorobenzyl)-(aminoiminomethyl) amine and 730 mg (2.4 mmol) Tetraethyl vinyl bisphosphonate was dissolved in 30 ml of toluene and 6 ml of dimethylformamide (DMF). 0.17 g (2.4 mmol) of anhydrous potassium carbonate was added thereto, and the mixture was heated to slump for 21 hours. The reaction solution was then filtered and concentrated in a rotary evaporator. 1.8 g of crude product was obtained. The material was purified on tapping tube columns. Use propanol as the eluent. Yield: 450 mg (35% of theoretical value) -27- ..................-: ............... ............................................. installation .. ....... TΓ line (please read the precautions on the back before filling in this page) This paper uses the National Standard (CNS) A4 specifications (210X297 mm) of the paper 295587 A6 B6 Central Bureau of Standards, Ministry of Economic Affairs Printed by Beigong Consumer Cooperative V. Description of the invention (26) Melting point: 146 to 149 ° C 31P_NMR spectrum: (CDCl3) 21_73ppm Example 4, 2-[(3,5-dichlorobenzyl)-(amino sub Aminomethyl) amino] ethane-1,1-bisphosphonic acid is prepared so that 350 mg (0.62 millimoles) of 2-[(3,5-difluorobenzyl)-(aminoiminomethyl Group) amino] ethane-U-bisphosphonic acid tetraethyl ester dissolved in 20 ml of acetonitrile. Under argon, 0.3 g of sodium iodide and 0.41 ml (3.10 mmol) of bromodimethylsilane were added. The mixture was stirred at room temperature for 16 hours, and then stirred at 40 ° C for 1 hour. Subsequently, the sodium bromide formed was filtered, and the mother liquor was freed from solvents and volatile substances at 40 ° C / 0.1 ° C. Add 20 ml of dichloromethane to the residue and filter the solid formed by suction filtration again. Exclude dichloromethane at 40 ° C /0.1 ° C. Then 15 ml of water was added and the mixture was sandalwood mixed at room temperature for 15 minutes. Drain water at 60 ° C / 12 degrees. Add 10 ml of isopropanol to the resulting residue and add about 1 to 2 ml of water. The mixture was heated for 5 minutes. After cooling, the colorless crystals were filtered by suction and dried under 12 dolmens. Yield: 170 mg (60%) Melting point: 267 ° C 31P-NMR spectrum: (Na0D / D20) < 5 31P = 19.09ppm iH-NMR spectrum: 28-^ ... ................................................ (Please read the precautions on the back before filling in this page) The paper scale is in accordance with Chinese National Standard (CNS) A4 specifications (210x297 mm) A6

經濟部中央樣準局貝工消费合作社印製 五、發明説明(27) (Na0D/D20) δ = 1.90 (tt, 2JPB - 14 H2, A „ 6 Hz, 1H); 3.48 (td, 3jm » 14 HZ| 3Jm β 6 Hz, 2H}; 7·45 (s, 1H); 7.54 (sf 2H). 31C-NMR 光譜: (Na0D/D20) δ = 43.8 (C-l); 44.1 (c-2); 129.9 (〇-3Ί; 133.0 (C-4); 136.7 (0-5/ C-5Ί ; 142.0 (C-6); 162.5 (C-Gua); 174.9 (C=〇). MS : m/e=419 實例5 曱基-2-吲哚羰基)_(胺、基亞胺甲基)胺基]乙烷_丨,卜 雙膦酸四乙醋 > —使ι·〇克(3.9毫莫耳n_甲基_2_吲哚羰基胍鹽酸鹽及12克(4 C莫耳)乙缔基一騰敗四乙醋;容於4〇毫升四氫吹喃(thf)及15 毫升二甲基甲醯胺(DMF)中。在其中添加〇55克(4毫莫耳)無 水碳酸鉀,混合物加熱至沸騰以小時。反應溶液隨後過濾 ,於旋轉恶發器中濃縮。得到2 〇克粗產物。物質於珍膠管 柱上純化。使用乙醇作為溶離液。 收量7 克(理論値之70%) 31p-NMR光譜: (CDC13) 5 =21.98ppm 實例6 2-[(1-甲基-2_會朶缓基)-(胺基亞胺甲基)胺基]乙燒_u_ -29- --.........................................................................................裝......................訂.....................線 (請先閲讀背面之注意事項再蜞寫本頁) _本紙張尺度適4中國®家標準甲4规格(210>< 297公*) A6 B6 經濟部中央標準局員工消費合作社印製 五、發明説明(28 ) 雙膦酸之製法 使得自實例5之1克((1.8毫莫耳)2-[(1 -甲基-2-吲哚羰基)-(胺基亞胺曱基)胺基]乙烷-U-雙膦酸四乙酯溶於40毫升乙 腈中。於氬氣下,在其中添加0.6克械化釣及1,2毫升(90毫 莫耳)溴三甲基矽烷。混合物於室溫下攪拌16小時後,於40 °C下攪拌1小時。過濾所形成之溴化鈉,於4〇°C/0.1鐸下, 排除母液中之溶劑及揮發性物質。添加2◦毫升二氣甲烷至 殘質中,再次抽吸過濾所形成之固體。於40 °C /0.1鐸下排 除二氯甲烷。添加15毫升水,混合物於室溫下攪拌15分鐘 。於60°C/12鐸下排除水。添加10毫升異丙醇至所得殘質中 ,添加約1至2毫升水。混合物加熱5分鐘。冷卻後,抽吸 過遽無色晶體,於12鐸下乾燥。 收量:300毫克(38%) 31P-NMR光譜: (Na0D/D20)5 31P=18.07ppm iH-NMR光譜: (Na0D/D20) δ >= 1.98 (tt, aJPH = 14 Hz, 3Jhh = 6 Hz, 1H); 3.65 (td, 3JPH » 14 Hz, 3Jhh = 6 Hz, 2H) ; 7.08 to 8.56 (aromatic Er 5). 13c-nmr 光譜: (Na0D/D20) δ = 32.5 (C-l); 41.8 (C-2); 41.9 (C-3); 103.2 (C-4); 105.2 (C-5); 120.2 (C-6); Ϊ22.0 (C-7); 124.1 (C-8); 126.2 (C-9) ; 137.8 (C-10); 139.2 (C-ll); 139.7 (C-12); 160.8 (C-Gua); 172.2 (C=0). —30 — 裝 .................訂...................'線 {請先閲讀背面之注意事項再填寫本頁) 本紙張尺度逋用中a國家標準(CNS)甲4規格(210X297公釐> 五、發明説明(29 ) A6 B6 經濟部中央搮準局員工消费合作社印製 MS : m/e-419實例7 2-[(3-甲磺醯基_4-苯氧苯曱醯基)-(胺基亞胺曱基)胺基] 乙烷-U-雙膦酸四乙酯之製法 依實例1所述,使1.8克(4.86¾莫耳)(3-甲績酿基-4-苯氧 苯甲醯基)-(胺基亞胺甲基)胺及1.46克(4.86毫莫耳)乙烯基二 膦酸四乙酿反應。 物質於碎膠管柱上層析。 使用乙酸乙酯:丙酮= 1:1為溶離液。 权量:800毫克(26%) 熔點:145°C 31P-NMR光譜: (CDC13) δ 31P=22.10ppm NMR光譜:(CDC13) δ = 1.35 (t, 12H); 3.31 (s, 3H)? 4.0 (me, 2H);4.20 (me, 9H); 6.88 (df 1H); 7.13 (me, 2H); 7.24 (me, 1H); 7.42 (me, 2H); 8.35 (d, 1H); 8.89 (s, 1H) ppm. 13C-NMR 光譜: -31 — 裝...........-..........訂.....................線 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐) A6 B6 經濟部中央標準局貝工消費合作社印製 五、發明説明(3Q)(CDCI3) δ = 16.43; 29.30; 37.89; 43.36; 53.87; 63.14; 117.25; 120.36; 125.33; 129.72; 130.25; 155.06; 157.82; 175.0 ppm.實例8 2-[(3-曱磺醯基-4-N,N-二乙胺基苯甲醯基)-(胺基亞胺 甲基)胺基]乙烷-U-雙膦酸四乙酯之製法 依實例1所述,使1.0兄(2.9毫莫耳)(3-甲磺醯基-4-N,N-二乙胺苯甲醯基)-(胺基亞胺甲基)胺及0.9克(2.9毫莫耳)乙烯 二膦酸四乙酯反應。 物質於矽膠管柱上層析。使用乙酸乙酯:丙酮=1:2為 溶離液。 - 收量:1_2克(66.6%) 熔點:121°C 31P-NMR 光譜: (CDC13) (5 31P=22.12ppm^-NMRT^tf ·'(CDC13) δ = 1.07 (t, 6H); 1.35 (t, 12H); 3.18 (q, 4H);3.34 (s, 3H); 3.98 (me, 2H); 4.20 (me, 9H); 7.32 (d, 1H); 8.36 (d, 1H); 8.92 (s, 1H) ppm. 13C-NMR 光譜: (CDC13) δ = 12.09; 16.38; 38.20; 42.59; 48.37; 63.34; 124.46; 137.21; 136.99; 153.34; 175.64 ppm. —32 — 苓.....................-ΤΓ..................…線 (請先閲讀背面之注意事項再填窝本頁) 本紙張尺度逋用中國國家標準(CNS)甲4規格(210x297公釐) 五、發明説明(31 ) A6 B6 貫例9 2-[(3-〒績酿基-4-苯氧苯甲酿基)-(胺基亞胺甲基)胺基] 乙烷-1,1-雙膦酸之製法_ 依實例2所述,使來自實例7之35〇毫克(0·55毫莫耳)2_[(3-甲磺醯基-4-苯氧苯甲醯基)-(胺基亞胺甲基)胺基]乙烷-U-雙膦酸四乙酯進行反應。 與4〇毫升水進行水解後之產物經抽吸過濾,並以3〇毫 升丙酮洗滌。 收量:150毫克(52·4%) 熔點:242°C ' 31p-nmr光譜: (NaOD/D2〇)5 31P=17.65ppm iH-NMR 光譜: (Na0D/D20) δ = 2.04 (ttf IB); 3.50 (s, 1H); 3.65 (td, 2H); 7.06 (d, 1H); 7.26 (d, 2H); 7.38 (me, 1H); 7.54 (me, 2H); 8.20 (me, 1H); 8.55 (m, 1H) ppm. 裝.......... !丨訂:..................線 {請先閲讀背面之注意事項再填寫本頁) 經濟部中央搮準局員工消费合作社印製 實例10 2-[(3-甲磺醯基~4-N,N-二乙胺苯甲醯基)-(胺基亞胺甲 基)胺基]乙烷-U-雙膦酸之製法 依實例2所述,使得自實例8之6〇〇毫克(〇.92毫莫耳)2-[(3- -33- 本紙張尺度適用中國國家標準(CNS)甲4规格(210x297公釐) 五、發明説明(32 A6 B6 甲磺醯基-4-N,N-二乙胺苯甲醯基)-(胺基亞胺甲基)胺基]乙 烷-U-雙膦酸四乙酯反應。 與30毫升水解後,抽吸過滤產物,並與丙酮混合。 收量:483毫克(100%) 熔點:181°C ' 31P-NMR光譜: (Na0D/D20) δ31Ρ = 17.70 ppm (2JPH « 20.9 Hz; 3Jph = 14.2 Hz) ifi-NMR光譜: (Na0D/D20) δ = 1.03 (t, 6H); 2.11 (tt, 1H); 3.12 (q, 4H); 3.53 (s, 3H)J 3.65 (td, 2H)? 7.58 (d, 1H); 8.26 (mcf 1H); 8.58 (m, 1H) ppm. 經濟部中央標準局員工消费合作社印製 實例11 根據本發明化合物之活性係依下列實驗在活體外證明 〇 分析2〇天大之胚胎鼠之頭蓋骨所釋出45 Ca決定骨再吸 收作用。解剖胚胎頭蓋骨前2天,將200 /Z Ci/Kg45CaCl2$ 射入懷孕老鼠體内,使骨骼標識45 Ca。 1.骨骼之培養 將胚胎頭蓋骨切成兩半,一半頭蓋骨作為對照組,且 另一半與根據本發明化合物培養。每一半頭蓋骨均在無菌 塑膠盤中培養。培養基(BGJb培養基,奇布可公司(Gibco)) — 34 — 裝.......................玎......................^ (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)甲4規格(210x297公釐) A6 B6 五、發明説明(33) 含有10%胎牛血清,盤尼西林/鏈徽素(100,000單位/升,奇 布可公司)及抗壞血酸(50毫克/升)。切半之頭蓋骨於37°C 下,含5%0〇2與95%〇2之氣體中培養。48小時後,以新鮮培 養基置換培養過之培養基,添加根據本發明化合物及甲狀 旁腺激素(ΗΓ7Μ),並續培養48小時。添加甲狀旁腺激素( 10_7 Μ ,希格馬公司(Sigma))至對照組中。實驗結束時,測 定培養基及骨骼中之45Ca。 表1中結果顯示抑制45 Ca釋入培養基中之百分比。其 結果為3至5個實驗之平均値。 表1 :抑制45Ca釋出之作用 產物濃度 產物 1〇1 io"8m io_6m 實例4 7% 21% 實例6 22% 29% 實例9 22% 21% 未測試 裝......................-ΤΓ.....................^ (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 — 35- 本紙張尺度適用中國國家標準(CNS)甲4规格(210X297公釐)Printed by Beigong Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 5. Description of invention (27) (Na0D / D20) δ = 1.90 (tt, 2JPB-14 H2, A „6 Hz, 1H); 3.48 (td, 3jm» 14 HZ | 3Jm β 6 Hz, 2H); 7.45 (s, 1H); 7.54 (sf 2H). 31C-NMR spectrum: (Na0D / D20) δ = 43.8 (Cl); 44.1 (c-2); 129.9 (〇-3Ί; 133.0 (C-4); 136.7 (0-5 / C-5Ί; 142.0 (C-6); 162.5 (C-Gua); 174.9 (C = 〇). MS: m / e = 419 Example 5 methyl-2-indolecarbonyl) _ (amine, iminomethyl) amino] ethane_ 丨, bisphosphonate tetraethyl acetate> — make ι · 〇 g (3.9 mmol) _Methyl_2_indolecarbonylguanidine hydrochloride and 12 g (4 C mol) of ethyl triethylpyrrolidone; contained in 40 ml of tetrahydrofuran (thf) and 15 ml of dimethyl To formamide (DMF). To this was added 055 grams (4 millimoles) of anhydrous potassium carbonate, and the mixture was heated to boiling for hours. The reaction solution was then filtered and concentrated in a rotary hair dryer. 20 grams of crude product were obtained. The material was purified on a Zhenjiao column. Ethanol was used as the eluent. Yield 7 g (70% of theoretical value) 31p-NMR spectrum: (CDC13) 5 = 21.98ppm Example 6 2-[(1-methyl-2 _Hui Duo (Slow base)-(aminoiminomethyl) amino] ethane_u_ -29- --................................ .................................................. ............. installed ...................... ordered ............. ........ Line (please read the precautions on the back before writing this page) _The paper size is suitable for 4 China® home standard A4 specifications (210 > < 297 g *) A6 B6 Central Ministry of Economic Affairs Printed by the Bureau of Standards and Staff Consumer Cooperative V. Description of the invention (28) The preparation method of bisphosphonic acid is such that 1 gram ((1.8 millimoles) 2-[(1-methyl-2-indolecarbonyl)-( Aminoiminomethyl) amino] ethane-U-bisphosphonic acid tetraethyl ester was dissolved in 40 ml of acetonitrile. Under argon, add 0.6 g of mechanical fishing and 1.2 ml (90 mmol) Ear) Bromotrimethylsilane. After the mixture was stirred at room temperature for 16 hours, it was stirred at 40 ° C for 1 hour. The sodium bromide formed was filtered and the solvent was removed from the mother liquor at 40 ° C / 0.1 Duo. And volatile substances. Add 2◦mL of methane gas to the residue, and suck and filter the solid again. Remove methylene chloride at 40 ° C /0.1°. 15 ml of water was added, and the mixture was stirred at room temperature for 15 minutes. Drain water at 60 ° C / 12 degrees. Add 10 ml of isopropanol to the resulting residue and add about 1 to 2 ml of water. The mixture was heated for 5 minutes. After cooling, suction through the colorless crystals, and dried at 12 Duo. Yield: 300 mg (38%) 31P-NMR spectrum: (Na0D / D20) 5 31P = 18.07ppm iH-NMR spectrum: (Na0D / D20) δ > = 1.98 (tt, aJPH = 14 Hz, 3Jhh = 6 Hz, 1H); 3.65 (td, 3JPH »14 Hz, 3Jhh = 6 Hz, 2H); 7.08 to 8.56 (aromatic Er 5). 13c-nmr spectrum: (Na0D / D20) δ = 32.5 (Cl); 41.8 ( C-2); 41.9 (C-3); 103.2 (C-4); 105.2 (C-5); 120.2 (C-6); Ϊ22.0 (C-7); 124.1 (C-8); 126.2 (C-9); 137.8 (C-10); 139.2 (C-ll); 139.7 (C-12); 160.8 (C-Gua); 172.2 (C = 0). —30 — Pack ... ............ Order .................. 'line (please read the notes on the back before filling this page) Use the Chinese National Standard (CNS) A4 specifications (210X297 mm> V. Description of the invention (29) A6 B6 Printed MS by the employee consumer cooperative of the Central Bureau of Economic Affairs of the Ministry of Economic Affairs: m / e-419 Example 7 2- [ (3-Methanesulfonyl-4-phenoxyphenmethyl)-(aminoiminomethyl) amino] ethane-U-bisphosphonic acid tetraethyl ester is prepared as described in Example 1, using 1.8 G (4.86¾ mol) (3-methylbenzyl-4-phenoxybenzyl)-(aminoiminomethyl) amine and 1.46 g (4.86 mmol) of vinyl diphosphonic acid tetraethyl Backlash The substance was chromatographed on a crushed rubber column. Using ethyl acetate: acetone = 1: 1 as the eluent. Weight: 800 mg (26%) Melting point: 145 ° C 31P-NMR spectrum: (CDC13) δ 31P = 22.10ppm NMR spectrum: (CDC13) δ = 1.35 (t, 12H); 3.31 (s, 3H)? 4.0 (me, 2H); 4.20 (me, 9H); 6.88 (df 1H); 7.13 (me, 2H) ; 7.24 (me, 1H); 7.42 (me, 2H); 8.35 (d, 1H); 8.89 (s, 1H) ppm. 13C-NMR spectrum: -31 — Pack ......... -............... Order ..................... line (please read the precautions on the back before filling out this page) Applicable to China National Standard (CNS) A4 specifications (210X297 mm) A6 B6 Printed by the Beigong Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs V. Description of Invention (3Q) (CDCI3) δ = 16.43; 29.30; 37.89; 43.36; 53.87; 63.14; 117.25; 120.36; 125.33; 129.72; 130.25; 155.06; 157.82; 175.0 ppm. Example 8 2-[(3-methylsulfonyl-4-N, N-diethylaminobenzyl)-(amine Iminomethyl) amino] ethane-U-bisphosphonic acid tetraethyl ester is prepared as described in Example 1, so that 1.0 brother (2.9 millimoles) (3-methanesulfonyl-4-N, N -Diethylaminobenzyl)-(aminoimine Yl) amine and 0.9 g (2.9 mmol) of ethylene diphosphonic acid tetraethyl ester reaction. The material was chromatographed on a silica gel column. Use ethyl acetate: acetone = 1: 2 as the dissolution solution. -Yield: 1_2 g (66.6%) Melting point: 121 ° C 31P-NMR spectrum: (CDC13) (5 31P = 22.12ppm ^ -NMRT ^ tf · '(CDC13) δ = 1.07 (t, 6H); 1.35 ( t, 12H); 3.18 (q, 4H); 3.34 (s, 3H); 3.98 (me, 2H); 4.20 (me, 9H); 7.32 (d, 1H); 8.36 (d, 1H); 8.92 (s , 1H) ppm. 13C-NMR spectrum: (CDC13) δ = 12.09; 16.38; 38.20; 42.59; 48.37; 63.34; 124.46; 137.21; 136.99; 153.34; 175.64 ppm. —32 — Ling ... .............- ΤΓ .................. line (please read the precautions on the back before filling the nest page) this The paper scale uses the Chinese National Standard (CNS) A4 specification (210x297 mm). V. Description of the invention (31) A6 B6 Example 9 2-[(3-〒 縒 縒 基 -4-Phenoxybenzoyl) -(Aminoiminomethyl) amino] ethane-1,1-bisphosphonic acid_ As described in Example 2, 35 mg (0.55 millimoles) 2 _ [( 3-Methanesulfonyl-4-phenoxybenzyl)-(aminoiminomethyl) amino] ethane-U-bisphosphonic acid tetraethyl ester. After hydrolysis with 40 ml of water The product was filtered with suction and washed with 30 ml of acetone. Yield: 150 mg (52.4%) Melting point: 242 ° C 31p-nmr spectrum: (NaOD / D2〇) 5 31P = 17.65ppm iH-NMR spectrum: (Na0D / D20) δ = 2.04 (ttf IB); 3.50 (s, 1H); 3.65 (td, 2H); 7.06 ( d, 1H); 7.26 (d, 2H); 7.38 (me, 1H); 7.54 (me, 2H); 8.20 (me, 1H); 8.55 (m, 1H) ppm. Pack ... ..! Order: .................. Line {Please read the precautions on the back before filling in this page) Printed example of the employee consumer cooperative of the Central Bureau of Economic Affairs of the Ministry of Economic Affairs 10 2-[(3-Methanesulfonyl ~ 4-N, N-diethylaminobenzyl)-(aminoiminomethyl) amino] ethane-U-bisphosphonic acid by example 2 described, so that 600 mg (〇.92 millimoles) from Example 8 2-[(3- -33- This paper scale is applicable to China National Standards (CNS) A 4 specifications (210x297 mm) V. Description of the invention (32 A6 B6 Methanesulfonyl-4-N, N-diethylaminebenzyl)-(aminoiminomethyl) amino] ethane-U-bisphosphonic acid tetraethyl ester reaction. After hydrolysis with 30 ml, the product was filtered with suction and mixed with acetone. Yield: 483 mg (100%) Melting point: 181 ° C '31P-NMR spectrum: (Na0D / D20) δ31P = 17.70 ppm (2JPH «20.9 Hz; 3Jph = 14.2 Hz) ifi-NMR spectrum: (Na0D / D20) δ = 1.03 (t, 6H); 2.11 (tt, 1H); 3.12 (q, 4H); 3.53 (s, 3H) J 3.65 (td, 2H)? 7.58 (d, 1H); 8.26 (mcf 1H); 8.58 (m, 1H) ppm. Printed by the Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs. Example 11 The activity of the compound according to the present invention was demonstrated in vitro according to the following experiment. Analysis of the 45 Ca released from the skull of a 20-day-old embryonic rat Decide on bone resorption. Two days before the dissection of the embryo skull, 200 / Z Ci / Kg45CaCl2 $ was injected into the body of the pregnant mouse to mark the bone with 45 Ca. 1. Bone culture The embryo skull is cut in half, half of the skull is used as a control group, and the other half is cultured with the compound according to the present invention. Each half of the skull is cultured in sterile plastic plates. Medium (BGJb medium, Gibco) — 34 — Pack ............................................ ............. ^ (Please read the precautions on the back before filling in this page) This paper scale is applicable to China National Standard (CNS) A4 specifications (210x297mm) A6 B6 V. Invention Description (33) Contains 10% fetal bovine serum, penicillin / streptavidin (100,000 units / liter, Chibuco) and ascorbic acid (50 mg / liter). The halved skull was incubated at 37 ° C in a gas containing 5% 0 2 and 95% 0 2. After 48 hours, the cultured medium was replaced with fresh medium, the compound according to the present invention and parathyroid hormone (HΓ7Μ) were added, and the culture was continued for 48 hours. Parathyroid hormone (10_7 Μ, Sigma) was added to the control group. At the end of the experiment, the 45Ca in the culture medium and bones was measured. The results in Table 1 show the percentage of inhibition of 45 Ca release into the medium. The result is an average value of 3 to 5 experiments. Table 1: Concentration of products inhibiting the release of 45Ca. Product concentration 10 1io " 8m io_6m Example 4 7% 21% Example 6 22% 29% Example 9 22% 21% Not tested ... ............- ΤΓ .................. ^ (Please read the precautions on the back before filling this page) Economy Printed by the Employees ’Consumer Cooperative of the Central Standards Bureau of the Ministry of Foreign Affairs — 35- This paper scale is applicable to the Chinese National Standard (CNS) Grade 4 (210X297 mm)

Claims (1)

申請專利範圍 專利申請案第83100925號 ROC Patent Appln. No.83100925 修正之申請專利範圍中文本一附件一 Amended Claims in Chinese — Enc 1. I Ί:氏固Μ十U月27 U达主J I---('S^jinniLted on November。,1995) 丨修丄Τ'84ΐί 1 . 个年角 B; ;補充 ( 1.具式la,lb,或Ic之互變異構型化合物 o: R o R H c ' I N I H Η I ΝΠ c .N I H I cno p H c R p V R o a o R oApplication for Patent Scope Patent Application No. 83100925 ROC Patent Appln. No. 83100925 Amended Claims in Chinese Scope 1 Annex 1 Amended Claims in Chinese — Enc 1. I Ί: Shigu M 10 U Month 27 U reach the main J I- -('S ^ jinniLted on November., 1995) 丨 Xiu Τ'84Ιί 1. Anniversary B;; Supplement (1. Tautomeric compounds of formula la, lb, or Ic o: R o RH c 'INIH Η I ΝΠ c .NIHI cno p H c R p VR oao R o N 1 c Η o I RN 1 c Η o I R (lb) ---------^------、玎------@ (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 R N I H一 c Π o H c I 2 N H m NIC ο Π p H c Η o 一 36 — R o R o R o R o 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 11(lb) --------- ^ ------ 、 玎 ------ @ (Please read the precautions on the back before filling out this page) Printed by the Staff Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs RNIH-c Π o H c I 2 NH m NIC ο Π p H c Η o-36 — R o R o R o R o This paper scale is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) 11 12 A8 B8 C8 D8 、申請專利範圍 及/或其生理上可耐受之鹽;其中 R具下列定義: I )如式V之基困 V) 式中 R11 表-S〇2-(Ci-C6)-垸基,且 R12表苯氧基、六氫破咬基或N((Gl_Ce)_炫基)2 H )如式VI之基團 I - ----- I ·. 1 .1 —-I— i I- - 1 I 二· 士-In H (請先閱讀背面之注悫事項再填寫本頁) *1T12 A8 B8 C8 D8, the scope of patent application and / or its physiologically tolerable salt; where R has the following definitions: I) as the basic V of formula V) where R11 Table-S〇2- (Ci-C6 ) -Alkyl group, and R12 represents a phenoxy group, a hexahydrocracker group or N ((Gl_Ce) _hyunyl) 2 H) such as the group VI of formula VI I------ I · 1.1.1 — -I— i I--1 I 2 · Shi-In H (Please read the notes on the back before filling this page) * 1T (VI) 式中R21、R22及R23分别獨立地代表氫或函素; 瓜)如式νπ之基團 VI!) 式中Y爲N(Ci-C6)-烷基; R5、R6、R7及R8爲相同或相異且分别獨立地爲氫原子 或(Cl-C4)-炫基。 _ 37.- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 線 經濟部中央標準局員工消費合作社印製 298587 --------申請專利範圍 ABCD 2. 如申請專利範圍第1項之化合物,其係選自下列任一者: 2 -〔(卜甲基~2-吲哚羰基)-(胺基亞胺甲基)胺基]乙烷—U-雙 膦酸四乙酯’ 2-[(卜甲基-2-吲哚基羰基)—(胺基亞胺甲基)胺 基]乙坑•-Ι,Ι-雙腾酸,、2-[(3-甲績酿基-4-六氫p比咬苯甲酿基)-.(胺基亞胺曱基)胺基]乙疼-1,1-雙膦酸,2-[(3-甲磺醯基-六氫吡啶苯甲醯基)-(胺基亞胺甲基)胺基]乙烷-1,1-雙膦酸 四乙酯,2-[(3,5-二氯苯甲醯基)-(胺基亞胺甲基)胺基】乙炫— 1,卜雙膦酸四乙酯,及二氣夢甲酿基)-(胺基亞胺甲 Γ 基)胺基]乙烷-1,卜雙膦綾。 3. —種製備根據申請專利範圍第1或2項之式I a ’ I b或I c 互變異構型化合物之方法,其包括: 使式IV化合物 一 R7 〇 — R IV C 二 C ^------II------.il (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印衆 \p___ 〇 — Rb 丨丨\〇 — R6 0 式中R5,R6,R7與R8如申請專利範圍第1項之定義’ A)與式瓜化合物於惰性溶劑之存在下反應 38.- 本纸張尺度適用中國國家標準(CNS ) A4規格(2丨0X297公釐) 申請專利祀圍(VI) where R21, R22 and R23 independently represent hydrogen or a functional element; melon) a group VI of formula νπ!) Where Y is N (Ci-C6) -alkyl; R5, R6, R7 and R8 is the same or different and is independently a hydrogen atom or (Cl-C4) -hyunyl. _ 37.- This paper scale is applicable to the Chinese National Standard (CNS) Α4 specification (210Χ297 mm) Printed by the Ministry of Economy Central Standards Bureau Employee Consumer Cooperative 298587 -------- Applicable patent scope ABCD 2. If applying for a patent The compound of item 1 in the scope is selected from any one of the following: 2-[(Bumethyl ~ 2-Indolecarbonyl)-(aminoiminomethyl) amino] ethane-U-bisphosphonic acid tetraethyl Ester '2-[(Bumethyl-2-indolylcarbonyl) — (aminoiminomethyl) amino] ethyl pit • -Ι, Ι-bis-teng acid, 2-[(3-methylglucoyl -4-hexahydrop is better than bitten benzyl)-. (Aminoiminomethyl) amino] acetone-1,1-bisphosphonic acid, 2-[(3-methanesulfonyl-hexahydro Pyridinebenzyl)-(aminoiminomethyl) amino] ethane-1,1-bisphosphonic acid tetraethyl ester, 2-[(3,5-dichlorobenzyl)-(amine Iminomethyl) amino] ethene-1, tetraethyl ethyl bisphosphonate, and Diqimeng methyl group)-(aminoimine methyl Γ) amino] ethane-1, bis bis Phosphine Aya. 3. A method for preparing a tautomeric compound of formula I a 'I b or I c according to item 1 or 2 of the scope of the patent application, which includes: using compound IV of the formula IV R7 〇- R IV C II C ^- -----II------.il (please read the precautions on the back before filling in this page) Printed by the Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs \ p ___ 〇— Rb 丨 丨 \ 〇— R6 0 R5, R6, R7 and R8 are as defined in item 1 of the patent application scope. A) Reaction with formula melon compounds in the presence of inert solvents 38.- This paper scale is applicable to China National Standard (CNS) A4 specifications (2 丨0X297mm) apply for patent siege C II 0 AS B8 C8 D8 nh2 N — C = NH 產生式I a,I b或I c化合物,其中如式J J .b或I c中之定義,且若適當時, B) 使式I a ’ I b或I C化合物之雙膦酸醋轉化成相應之雙膦 酸,或 , 使式IV化合物,式中FT5,R6,R7皋R8如式〗3之定義, C) 與式疆化合物於惰性溶劑之存在下反應 2 1C II 0 AS B8 C8 D8 nh2 N — C = NH produces compounds of formula Ia, Ib or Ic, where as defined in formula JJ.b or Ic, and if appropriate, B) makes formula Ia ' The bisphosphonate of I b or IC compound is converted to the corresponding bisphosphonate, or, the compound of formula IV, where FT5, R6, R7 and R8 are as defined in formula 3, C) and the compound of formula Xinjiang in an inert solvent React in the presence of 2 1 nh2N — C- N Η VIII 經濟部中央標準局員工消費合作社印製 產生式I a,I b或I C化合物,式中r21,R22&R23如式工 a,I b或I c之定義,且若適當時, D) 使式I a ’ I b或I、c化合物之雙膦酸酿轉化成相應之雙騰 酸,或 使式IV化合物,式中R5,R6 ’ R7與R8如式I a中之定義 E) 與式K化合物於惰性溶劑之存在下反應 ------------裝------訂丨-----線 (請先閲讀背面之注意事項再填寫本頁) 39.- 本紙張尺度適用中國國家標準(CNS)A4規格(210X297公嫠) 8 8 8 8 ABCD 295587 六、申請專利範圍nh2N — C- N Η VIII The Ministry of Economic Affairs Central Standards Bureau employee consumer cooperative printed and produced the compound of formula I a, I b or IC, where r21, R22 & R23 are as defined in formula a, I b or I c, and if Where appropriate, D) convert the bisphosphonic acid of the compound of formula I a 'I b or I, c into the corresponding bisphosphonic acid, or the compound of formula IV, where R5, R6' R7 and R8 are as in formula I a Definition E) React with the compound of formula K in the presence of an inert solvent ------------ installed ------ order 丨 ----- line (please read the notes on the back first (Fill in this page again) 39.- This paper scale applies the Chinese National Standard (CNS) A4 specification (210X297 public daughter) 8 8 8 8 ABCD 295587 VI. Scope of patent application NH, I C = NH (IX) 產生式la,lb或lc化合物,式中γ具有如式丨a,丨匕或 丨c中之定義,且若適當時, F)使式I a,I b或I Hb合物之雙膦酸酯轉化成相應之雙膦 酸。 4· 一種用於治療及預防變質性骨骼病變之醫藥组合物, 其含有有效量之至少一種如申請專利範圍第1項之式 丨a,lb或lc之互變異構型化合物,及/或至少一種式 丨a,lb或lc互變異構型化合物之生理上可耐受之鹽, 及醫藥上可接受且生理上可耐受之輔助物質,及/或賦 形劑,稀釋劑與/或其他活性物質。 -----------裝------訂 镍 (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標隼局員工消費合作社印製 -40.- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)NH, IC = NH (IX) produces a compound of formula la, lb or lc, where γ has the definition as in formula 丨 a, 丨 dagger or 丨 c, and if appropriate, F) makes formula I a, I b or The bisphosphonate of the I Hb compound is converted to the corresponding bisphosphonate. 4. A pharmaceutical composition for the treatment and prevention of degenerative skeletal lesions, which contains an effective amount of at least one tautomeric compound of the formula 1, a, lb or lc, as claimed in item 1 of the patent application, and / or at least A physiologically tolerable salt of a tautomeric compound of formula 丨 a, lb or lc, and pharmaceutically acceptable and physiologically tolerable auxiliary substances, and / or excipients, diluents and / or other Active substance. ----------- installed ------ order nickel (please read the precautions on the back before filling this page) Printed by the Ministry of Economic Affairs Central Standard Falcon Bureau Employee Consumer Cooperative -40.- This paper The scale is applicable to China National Standard (CNS) A4 specification (210X297mm)
TW83100925A 1992-12-02 1994-02-04 TW295587B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE424022 1992-12-02
DE19934316019 DE4316019A1 (en) 1993-05-13 1993-05-13 Benzoylguanidine alkyl-1,1-bisphosphonic acids, process for their preparation and their use
DE4332362 1993-09-23

Publications (1)

Publication Number Publication Date
TW295587B true TW295587B (en) 1997-01-11

Family

ID=51565268

Family Applications (1)

Application Number Title Priority Date Filing Date
TW83100925A TW295587B (en) 1992-12-02 1994-02-04

Country Status (1)

Country Link
TW (1) TW295587B (en)

Similar Documents

Publication Publication Date Title
JP3499905B2 (en) Guanidine alkyl-1,1-bisphosphonic acid derivatives, their preparation and use
JP2019218356A (en) Carbidopa and l-dopa prodrugs and method of use thereof
JPH05186481A (en) New vanadium complex, its preparation and medicinal composition containing same
EP2522654A2 (en) Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient
HU197735B (en) Process for producing ascorbinic acid derivatives and pharmaceutical compositions containing them
RU2124519C1 (en) Derivatives of guanidinealkyl-1,1-bis-phosphonic acid, method of their synthesis, drug and method of its synthesis
KR20090024212A (en) Phosphine transition metal complex, method for producing the same and antitumor agent
RU2042659C1 (en) Method of synthesis of 1-aryl-2-arylhydroxyethane derivatives
TW200407310A (en) Compounds
FR2752841A1 (en) PROCESS FOR THE PREPARATION OF 3-AMINO-1-HYDROXYPROPANE- 1,1-DIPHOSPHONIC ACID
US3947446A (en) Novel 1-[3-(5,6,7,8-tetrahydronaphth-1-yloxy)-propyl]-piperazine compounds and therapeutic compositions
TW295587B (en)
WO2007066557A1 (en) Phosphine transition metal complex, method for producing same and antitumor agent containing same
IE58413B1 (en) Polyprenyl compounds, processes for preparing them, and pharmaceutical composition containing them
JP6867998B2 (en) Substituted hydrophobic benzenesulfonamide thiazole compounds for use in treating cancer
HU215436B (en) Process for preparing n-[(4,5-dihydroxi-9,10-dihydro-9,10-dioxo-2-anthracene-yl)carbonyl]amino acids and pharmaceutical compositions containing them as active agent
CN105439966B (en) Compound and its preparation method and application
EP3964514A1 (en) Ginkgolide b derivative and salt thereof, preparation method therefor and use thereof
CA1076482A (en) Active derivatives of methylamine, therapeutic compositions containing the same and processes for preparing the said derivatives and compositions
WO2012075927A1 (en) Thiazolamine derivative and use thereof as anti-picornaviral infection medicament
WO2012154392A1 (en) Metformin salts of salicylic acid and its congeners
IL43726A (en) 1-phenoxy-3-(p-carbamoylphenoxy)ethylamino-2-propanol derivatives and pharmaceutical compositions containing them
GB2100261A (en) Aminophenylalkylamine derivatives, a process for their preparation and their use as pharmaceuticals
US5037828A (en) Piperazine derivatives, uses thereof and pharmaceutical compositions containing them
FI65261B (en) FOERFARANDE FOER FRAMSTAELLNING AV FARMAKOLOGISKT ANVAENDBART DINATRIUMSALT AV N- (FOSFONOACETYL) -L-ASPARAGINSYRA